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Abstract 
Exogenous growth promotants, such as the synthetic beta agonist zilpaterol hydrochloride 
(ZH), have been shown to increase carcass weight by repartitioning energy toward increased 
skeletal muscle at the expense of adipose tissue, which is associated with a decline in tenderness. 
More recently, essential oils such as menthol have been observed to have growth promoting 
properties in livestock. The objectives of this research were to determine effects of ZH on blood 
parameters and long chain fatty acids in plasma and adipose tissue, to determine if the decline in 
tenderness can be negated by temporary depletion of calcium during ZH supplementation, and to 
determine effects of crystalline menthol on blood parameters. Blood samples were collected in 7-
d intervals during ZH administration. Zilpaterol hydrochloride decreased concentrations of 
plasma urea nitrogen and whole blood glucose (P < 0.10), but had no effects on concentrations of 
plasma glucose, lactate, beta-hydroxybutyrate, NEFA, or whole blood lactate (P > 0.10). Total 
long chain fatty acids of plasma and adipose tissue were unaffected (P > 0.10); however, ZH 
supplementation increased HCW, dressing percentage, and LM area (P < 0.10). Calcium was 
temporarily depleted during ZH supplementation in an attempt to increase tenderness of meat. 
No differences (P > 0.10) were observed for Warner-Bratzler shear force values, live animal 
performance, or carcass measurements. Addition of 0, 0.003, 0.03, 0.3% menthol (diet DM) to 
diets of steers resulted in a menthol × time within day interaction (P < 0.01) for IGF-1 
concentration and BW; however, glucose, lactate, and PUN concentrations were unaffected (P > 
0.05). Furthermore, concentrations of VFA were not different (P > 0.05), but production of 
fermentative gas was decreased (P < 0.01) when menthol was added at 0, 0.003, 0.03, 0.3% of 
substrate DM in a 24 h in vitro fermentation trial. Results from these studies suggest ZH 
improved efficiency of nutrient utilization for increased skeletal muscle growth; however, the 
decline in tenderness was not negated by the temporary depletion of calcium in the diet. Overall, 
ZH affected components related to increased skeletal muscle growth, but menthol did not affect 
blood parameters associated with growth.
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 Abstract 
Beta agonists have been utilized in research trials with livestock since the 1980’s as 
repartitioning agents, increasing the deposition of lean tissue in comparison to adipose tissue. In 
mammalian tissue, 3 subtypes of beta-adrenergic receptors (β-AR) exist: β1-AR, β2-AR, and β3-
AR. Different tissues within animals vary with respect to different distributions of β-AR, and 
therefore respond differently with administration of β-adrenergic agonists (β-AA). For example, 
the heart and digestive tract contain greater proportions of β1-AR relative to β2-AR or β3-AR, 
whereas lung and skeletal muscle contain greater proportions of β2-AR, and adipose tissue 
contains primarily β3-AR. Due to the wide range of tissues containing β-AR, different systems 
within the body of ruminants are affected with β-AA administration. Calves treated with 
different β-AA and had respiratory parameters measured. In treated calves there was an initial 
increase in respiration rate with oral administration of β-AA; however, this effect was 
diminished with chronic exposure. Lambs treated with terbutaline had higher liquid clearance 
from their lungs. The digestive system has not responded consistently to β-AA administration. In 
some instances contractile activity is unchanged, whereas in other studies smooth muscle 
contraction is altered. Fermentation responses within the rumen microorganisms varied between 
trials suggesting rumen microorganisms respond differently to different β-AA. Furthermore, 
carcass composition is altered with administration of β-AA. In general, an increase in lean tissue 
mass is observed while adipose tissue is either decreased or not affected depending on type of β-
AA administered. Differences observed in the literature may be due to many factors which 
include: species, age of animal, weight of the animal, and/or genetics, β-AA administered, 
dosage of β-AA, duration of treatment. All of which make comparing β-AA, and trying to 
quantify physiological responses difficult. 
Key words: beta-adrenergic agonists, beta-adrenergic receptors, ruminants  
 Introduction 
Adrenergic receptors (AR) are membrane-bound receptors located on the cell surface of 
most cells throughout the body. Naturally occurring catecholamines (i.e. epinephrine, and 
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norepinephrine) and sympathomimetic drugs exert their physiological effects by binding these 
receptors (Badino et al., 2005). In the late 1940’s, AR were characterized into two types, α- and 
β-adrenergic receptors, based on excitatory or inhibitory responses to catecholamines (reviewed 
by Badino et al., 2005). Primary responses observed during alpha adrenergic receptor activation 
include maintenance of vascular tone, blood pressure, glucose homeostasis, and contraction of 
vascular smooth muscle (Badino et al., 2005). Due to the diversity of cells in which receptors are 
located, every body system is affected with beta-adrenergic agonist (β-AA) administration. 
Three β-receptor subtypes have been identified: β1, β2, and β3-AR, and distribution of  subtypes 
varies among tissues. For example, the heart contains primarily β1-AR, whereas skeletal muscle 
contains more β2-AR, and adipose tissue contains predominantly ß3-AR; therefore, the effect of 
each agonist varies depending on which β-AR is affected (Badino et al., 2005). Distributions of 
receptor subtypes also vary among species, making it difficult to extrapolate information from 
humans to livestock (Badino et al., 2005). Beta-adrenergic agonists administered to livestock are 
orally active, and general responses observed are: 1) increased ADG; 2) improved feed 
efficiency; 3) decreased adipose tissue; and 4) increased dressing percent (Moody et al., 2000). 
Although responses within the muscular system are most commonly studied, other organ systems 
within treated animals are affected by oral administration of β-AA. The purpose of this review is 
to summarize effects of β-AA on digestive, respiratory, endocrine, and muscular systems of 
ruminants. 
 Beta-Receptor classification and activation 
In 1948, Ahlquist discovered 2 types of receptors on smooth muscle for which 
catecholamines, such as epinephrine and norepinephrine, exerted excitatory or inhibitory effects. 
Classification of the receptors was based on potency of different agonists in stimulating 
responses (Stiles et al., 1984). These receptors were classified as α- or β-receptors (Badino et al., 
2005). In 1967, β-ARs were further subdivided into β1 or β2 subtypes based on their affinity for 
epinephrine or norepinephrine. Beta1 receptors, commonly found in cardiac tissue, had equal 
affinities for both epinephrine and norepinephrine, whereas β2 receptors, found in the trachea and 
vasculature, had greater affinity for epinephrine compared to norepinephrine. Additionally, both 
receptor subtypes can exist in the same organ or tissue (Badino et al., 2005). In 1989, another β-
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AR was identified leading to designation of the β3-AR subtype for which norepinephrine is more 
stimulatory than epinephrine (Emorine et al., 1989). Distribution of receptor subtypes varies 
greatly among tissue types and animal species. Beta2 receptors found in the smooth muscle of 
lungs are responsible for relaxation, conferring an important role of β2-AA for control of asthma 
in humans. Agonists primarily affecting β1 and β2 receptors have been used in human health for 
the treatment of cardiac inotropic support, asthma, and as uterine relaxants (Moody et al., 2000). 
Beta3 receptors were found in rat adipose tissue, and most likely are involved with regulation of 
lipolysis and body temperature (Badino et al., 2005).  
The different classifications of β-AR have been confirmed with ligand binding studies. In 
1974, the first successful radioactively labeled β-antagonist was evaluated (Stiles et al., 1984).  
A summary of common radioligands used for β-receptor studies is found in table 1.1. 
Researchers use antagonist radioligands to study adrenergic receptor abundance and properties, 
and agonist radioligands for researching mechanisms of action of agonist attachment to 
adrenergic receptors (Stiles et al, 1984). Additionally, researchers have been able to study the 
differences in receptor subtype. Use of β1 or β2 specific ligands has made it possible to 
accurately assess relative proportions of receptor types within a given tissue.  
Binding of agonists to β-AR located on cell surfaces causes a cascade of events to occur. 
First, binding of agonist to receptor stimulates G-proteins to activate adenylate cyclase. 
Adenylate cyclase then synthesizes cAMP, the intracellular messenger for receptors (Mersmann, 
2002). Different mechanisms of action occur depending on tissue type after synthesis of cAMP. 
In general, cAMP binds to the regulatory unit of protein kinase A to release its catalytic subunit 
(Moody et al., 2000). Phosphorylation of protein kinase A regulates cellular enzymes, including 
hormone-sensitive lipases and lipogenic enzymes (Moody et al., 2000). The cAMP response 
binding protein (CREB) is also phosphorylated by protein kinase A and initiates transcription for 
a number of genes in mammalian tissues (Mersmann, 1998). Phosphorylation causes some 
enzymes, including the rate limiting enzyme for long-chain fatty acid biosynthesis, acetyl-CoA 
carboxylase, to become inactive (Mersmann, 1998).  Examples of physiological effects include 
regulation of heart rate and blood pressure, bronchial muscle contraction or relaxation, uterine 
contractions or relaxation, and in the case of food animals, increased skeletal muscle accretion. 
Due to the wide distribution of β-AR in mammalian tissues, effects observed in vivo may be 
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primary and secondary in nature, caused by β-AA binding to receptors in one type of tissue or in 
combination with binding of receptors in another tissue (Mersmann, 1998). For example, direct 
effects of β-AA on skeletal muscle may be augmented through indirect effects on vasculature 
that increase blood flow to skeletal muscle, thus making more nutrients available to support 
muscle accretion.  
Chronic exposure to β-AA causes cells to become desensitized, thus decreasing response 
to β-AA. Different mechanisms for desensitization can occur: functional uncoupling of 
receptors, physical sequestration of receptors away from the cell surface, and down regulation of 
the number of receptors (Badino, 2005). The time frame over which this can occur is seconds to 
hours after exposure; however, response to β-AA administration is not eliminated completely.  
 Respiratory system 
Beta-agonists have been used for many years in treatment of human asthma, and effects 
on respiratory function have been extensively researched. Beta2 receptors are the predominant 
receptor involved in bronchodilation, whereas cardiac effects are mediated through β1 receptors. 
Beta2 agonists were introduced in the 1960’s as a means of controlling asthma without the 
common side effect of increased heart rate (Barnes, 1988). The primary benefits of treating 
asthma using β2-agonists are bronchodilation (Barnes, 1997) and production of surfactant by 
mucous cells lining airway smooth muscle (Enhoning, 2008). In the early 1980’s, synthetic β-
agonists made their entry into livestock research trials as growth stimulants. Ricks et al. (1984) 
were among the first to administer synthetic β-AA to livestock and observe their effects on 
carcass composition in several meat animal species including cattle (Mersmann, 2002). The 
effect on body composition has been extensively researched (Ricks et al., 1984; Beermann et al., 
1987; Avendaño-Reyes et al., 2006); however, effects of β-AA on the respiratory system in 
cattle is poorly understood. 
Beta-agonist treatment caused respiration rate to increase in cattle. Blum and Flueckiger 
(1988) administered P-5369 and Q-2636 orally in milk replacer of calves and observed an 
increased respiration rate at h 5, 6.5, and 8 with addition of P-5369 (P< 0.05), and h 3.5, 6.5, and 
8 with Q-2636 (P < 0.05) compared to control counterparts. Similarly, Zimmerli and Blum 
(1990) fed the β-AA T-3660 (group T) and  P-5369 (group P) to calves and observed 50 to 60% 
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rise in respiration rate on d 0 and 28 for calves in group T (P < 0.05) compared to control calves, 
but calves in group P were not affected (P > 0.05). Bruckmaier and Blum (1992) observed 
increased respiration rates in calves treated with clenbuterol before during, and, after exercise on 
d 1, 14, and 35 (P ≤ 0.05) when compared to calves with no β-AA. Substance P-5369 was later 
found to be clenbuterol, and was classified as primarily a β2-agonist (Blum and Flueckiger, 
1988). Substances Q-2636 and T-3660 had no data available for comparable characterization, but 
have been shown to have β2-agonist activity as evident by their action on respiration rate. 
Respiration minute volume (RMV) was affected with oral administration of β-AA. 
Respiratory minute volume is the amount of new air entering the lungs each minute. Substances 
P-5369 and Q-2636 increased RMV in treated calves h 2 thru 8 (P < 0.05) when compared to 
control calves (Blum and Flueckiger, 1988). Correspondingly, Zimmerli and Blum (1990) fed 
the β-AA T-3660 and P-5369 to calves for 28 d and observed an increase in RMV of treated 
calves compared to control calves 6 h after administration of both β-AA (P < 0.05); however, 
after d 28 of treatment this effect persisted only in calves treated with T-3660 (P < 0.05). These 
results may indicate greater β2-receptor activity for T-3660 compared to P-5369 due to 
differences on d 28 in RMV. Bruckmaier and Blum (1992) performed a study assessing 
respiration parameters during exercising of calves that received 0 or 25 mg/kg BW clenbuterol. 
Respiratory minute volume was higher in clenbuterol treated calves on d 1 and 14 up to 12 min 
of exercise and remained higher during recovery (P ≤ 0.05), but was elevated for only 6 min of 
exercise on d 35 (P ≤ 0.05) compared to control calves. Results from these studies suggest initial 
exposure to β-AA cause the greatest change in RMV, but as administration persists subtle 
differences were observed indicating possible tachyphylaxis. Direct effects of β-AA on lung 
tissue could have modulated the differences observed in respiration parameters (Blum and 
Flueckiger, 1988). 
Berthiaume et al. (1987) performed a study using anesthetized sheep. Sheep were 
surgically fitted with tracheosotomy tubes to assess whether or not the β2-agonist terbutaline 
could increase lung liquid clearance. Addition of terbutaline mixed with a serum solution added 
directly to air spaces in the lungs decreased (P < 0.05) water accumulation in the lungs compared 
to lungs of sheep instilled with serum alone. Additionally, when terbutaline was administered 
intravenously the amount of excess liquid measured in the lungs was less than that of serum 
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infusion (P < 0.05). These results were confirmed to be due to the action of β-AR through use of 
propranolol (beta blocker). The authors hypothesized that the mechanism of action was through 
induction of sodium transport by the sodium-potassium pump located on the interstitial side of 
the plasma membrane. Movement of sodium out of the lumen in the lungs caused water and 
chloride to passively move through the cells, following the movement of sodium.  
Results of these studies lead to the conclusion that addition of β-AA does have an initial 
effect, causing an increase in respiration rate. Depending on β-AA administered, cells located in 
lungs can become desensitized. In addition, ruminants that have or have had respiratory disease 
problems may benefit from the addition of β-AA as suggested by the results of Berthiaume et al. 
(1987). 
Digestive system 
 Naturally occurring catecholamines, norepinephrine and epinephrine, affect gut motility 
by increasing or decreasing motility (Leek, 2001). Phenethanolamines may act in a manner 
similar to that of catecholamines. Miert (1968) observed α and β-AR in the ruminal wall. Strips 
taken from the dorsal sac of the rumen in sheep were treated with oxymetazoline hydrochloride 
for α-receptor stimulation, or isoprenaline hydrochloride for β-receptor stimulation (Miert, 
1968). Miert (1968) concluded α- receptors caused a stimulatory response, and β-AR caused an 
inhibitory response in ruminal smooth muscle.  
Leek (2001) suggested beta1-receptors mediate inhibition of gastric centers and β2-
receptors mediate inhibition of intrinsic and extrinsic motility of the reticulorumen. 
Rumenoreticular motility was analyzed in Holstein calves by Guard et al. (1988). No effect was 
observed (P > 0.05) for ruminal motility with addition of clenbuterol, indicating clenbuterol does 
not have inhibitory actions on forestomach motility of healthy calves. On the other hand, Ricks 
et al. (1984) observed a decrease in rumen fermentation (P ≤ 0.01) with addition of 500 mg/d 
clenbuterol to the diet of steers compared to steers without clenbuterol. The authors suggested 
decreased fermentation may have been caused by decreased ruminal motility. Brikas et al. (1990) 
infused doputamine, a β1-AA, intravenously to sheep and observed a decrease in frequency of 
reticular, ruminal, and abomasal contractions, but an increased number of contractions in the 
duodenum (P < 0.05). When the authors infused ritodrine, a β2-AA, there was no difference on 
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motility in forestomach or jejunum, but the frequency at which abomasal contractions occurred 
was reduced (P < 0.05) compared to control ewes. These findings may be due to the gastro-
intestinal tract containing primarily β1-receptors (Brikas, 1989). Ritodrine and clenbuterol are 
primarily β2-AA, which would explain the lack of effect on gastro-intestinal motility. 
 Moloney et al. (1994) measured ruminal digesta kinetics (liquid volume, ammonia, 
liquid outflow rate, solid outflow rate, and mean retention time of liquid and solids) to measure 
the impact of cimaterol, primarily a β2-agonist, on digesta passage. Steers were fed 0 or 15 
mg/kg cimaterol for a 35-d feeding period. The authors observed no differences among 
treatments (P > 0.05), leading them to conclude passage rate from the rumen was not affected by 
cimaterol due to the lack of effect on ruminal motility.  
Beta-agonists may act directly on receptors in the gastro-intestinal tract to decrease 
contractions thereby increasing retention time and potentially increasing digestion (Brikas, 
1989). Fiems et al. (1991) observed a decrease (P < 0.05) in crude fiber digestibility in sheep, 
and a decrease (P < 0.05) in crude fiber, DM, and OM digestibility in bulls when both species 
were fed cimaterol. These findings were attributed to an increased rate of passage for bulls fed 
ad libitum, whereas sheep were fed a limited diet, therefore decreasing the rate of passage. 
Similarly, Chikhou et al. (1991a) observed a decrease (P < 0.001) in DM digestibility, with no 
effect observed for crude fiber, NDF, ADF, or CP digestibility (P > 0.05) with addition of 
cimaterol to the diet of steers fed a limited diet. Walker et al. (2007) performed a study that fed 
200 mg/d ractopamine for 28, 29, and 30 d to steers. The authors observed an increase in DM 
digestibility (P < 0.05) with addition of ractopamine. Furthermore, nitrogen intake, fecal nitrogen 
output and urinary nitrogen output decreased (P < 0.05) when compared to control cattle, 
indicating increased nitrogen retention. Increased DM digestibility is in agreement with Brikas 
(1989), suggesting β-AA act on β-receptors in the gastrointestinal tract to decrease contractions 
and increase retention time (Walker et al., 2007). López-Carlos et al. (2010) performed a study in 
which lambs were supplemented with 0.35, 0.70, 1.05 mg/kg BW ractopamine or 0.1, 0.2, 0.3 
mg/kg BW zilpaterol. The authors observed no differences in DM, CP, ADF, or NDF 
digestibility (P > 0.05) with either β-AA. They concluded addition of β-AA to the diet of sheep 
does not compromise digestibility. Due to differences in amount of feed offered to animals it is 
difficult to extrapolate information and determine if differences in effects observed between 
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studies are due to β-AA treatment, rate of passage, or both; however, species differences are 
evident. 
Ruminal fermentation was reviewed in more detail due to the important role of 
fermentation in the digestion process of ruminant animals, and conflicting results were observed. 
Inclusion of clenbuterol to diets of steers had no effect (P > 0.05) on ruminal fermentation when 
samples were collected at the time of slaughter (Ricks et al., 1984). Similarly, Moloney et al. 
(1994) analyzed ruminal fermentation in sheep fed ad libitum with 0 or 10 mg/kg diet DM 
cimaterol for 64 d. They observed no change in concentrations of acetate, propionate, or butyrate 
(P > 0.05); however, concentration of valerate was less (P < 0.01) in treated lambs. The authors 
regarded the decrease in valerate as unimportant due to the minor role of valerate as a 
fermentative end product. Moloney et al. (1994) fed a pelleted ration that contained 0 or 15 
mg/kg cimaterol to steers, and intake was maintained at 15.5 g DM/kg BW fed twice daily. 
Ruminal fluid samples were collected on d 17 and 21 at 2, 4, 8, 12, 16, and 24 h after feeding. 
Addition of cimaterol to the diet caused a cimaterol × time interaction for acetate, propionate, 
and butyrate (P < 0.001), but concentration of valerate was not different from control animals (P 
> 0.05). Molar proportion of acetate was higher (P < 0.05) 12 h after the first feeding with 
addition of cimaterol, but was not different at other times. The molar proportion of propionate 
was higher at h 8, 12, and 16 (P < 0.01) in animals fed cimaterol, and the molar proportion of 
butyrate was lower (P < 0.05) in cimaterol fed steers 12 and 16 h after the first feeding. The 
authors concluded cimaterol had a small but beneficial effect on the concentrations of ruminal 
VFA. Fiems et al. (1991) conducted a trial that measured VFA content in sheep fed at 
maintenance level with 0 or 4 mg/kg diet DM cimaterol. Ruminal fluid samples were collected 4 
consecutive days at 2.5 h after feeding. They observed increased concentrations of propionic and 
acetic acid, and a decreased concentration of butyric acid (P < 0.05) in cimaterol treated sheep. 
The data suggest ruminal microorganisms respond to β-AA treatment; however, the response is 
not consistent between studies. Differences may be due to diurnal variation in rumen 
fermentation, amount of feed offered, or species differences. 
Walker and Drouillard (2010) conducted an experiment in vitro to assess impact on 
mixed ruminal microbes with addition of ractopamine to substrate. The authors observed an 
increase in gas production up to 22.6 mg/L ractopamine (P < 0.05), but no differences in acetate, 
propionate, or butyrate acid concentrations (P > 0.05). Additionally, a ractopamine × time of 
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fermentation interaction was observed when analyzing IVDMD (P < 0.01). Cultures containing 
ractopamine had greater DM disappearance suggesting ractopamine stimulates fermentation by 
rumen microbes. 
 Metabolic Effects 
Metabolic parameters have been measured in an effort to explain shifts in carcass 
composition commonly observed with β-AA administration. Common metabolites measured 
include glucose, NEFA, and BUN concentration. Analyzing NEFA content can be used as an 
indicator of fatty acid oxidation, where low concentrations are normally found in blood, but 
increased concentrations indicate catabolism of adipose tissue. Beermann et al. (1987) measured 
NEFA concentration in lambs fed 10 mg/kg cimaterol. The authors observed a 60% increase in 
NEFA concentration in lambs receiving cimaterol when compared to control lambs (P < 0.01).  
Similarly, Blum and Flueckiger (1988) fed P-5369 and Q-2636 to calves through milk replacer 
and observed an increase in NEFA concentration (P < 0.05) up to 4 h after administration of P-
5369; followed by a return to basal levels. Administration of Q-2636 resulted in an increase in 
NEFA concentration (P < 0.05) up to 6 h compared to control calves. Additionally, Chikhou et 
al. (1991b) observed increased NEFA concentration d 1 and 13 (P < 0.05), but NEFA were not 
different on d 20 (P > 0.05) for animals with and without orally administered cimaterol. In 
agreement with theses findings, Zimmerli and Blum (1990) observed a postprandial increase in 
NEFA concentration (P < 0.05) on d 1 of administration of β-AA T-3660 and P-5369, but no 
differences at later sampling points when compared to control animals. These results suggest 
chronic exposure to β-AA may cause desensitization of receptors in adipose tissue. The 
consistent increase in NEFA concentration in plasma with addition of β-AA suggests lipolysis is 
occurring in treated animals, and may be in combination with decreases in re-esterification or 
uptake of free fatty acids from circulation (Chikhou et al., 1991b). Increased blood flow with β-
AA administration may contribute to decreased free fatty acid uptake and increased beta 
oxidation by skeletal muscle. 
Glucose is an important energy substrate for skeletal muscle development (Du et al., 
2010); however, β-AA treatment has minor effects on plasma glucose concentrations. Beermann 
et al. (1987) measured glucose concentration in lambs fed 10 mg/kg cimaterol, and observed no 
change in plasma glucose concentration (P > 0.01). Likewise, Quirke et al. (1988) observed 
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blood concentrations of glucose to be unaffected by administration of cimaterol (P > 0.05) to 
steers for 85 d. These results suggest animals may be able to regulate blood glucose levels more 
closely when compared to BUN or plasma NEFA concentration, which may explain the lack of 
effect of β-AA on plasma glucose concentrations. Blum and Flueckiger (1988) fed P-5369 and 
Q-2636 to calves through milk replacer and observed increased concentrations of glucose up to 
10 h after administration (P < 0.05) of either β-AA. Similarly, Chikhou et al. (1991b) observed 
increases in plasma glucose concentrations on d 1 (P < 0.05) compared to control animals, but 
concentrations did not differ among treatments on d 13 and 20 (P > 0.05). Zimmerli and Blum 
(1990) observed a postprandial increase in glucose (P < 0.05) on d 1 of administration of T-3660 
and P-5369 to calves, but no further changes on following sampling days. In disagreement, 
Walker et al. (2007) observed a tendency (P = 0.08) to decrease plasma glucose with 
ractopamine administration to steers, while Walker et al. (2010) demonstrated ractopamine had 
no effect on plasma glucose concentrations in steers (P = 0.34). Early effects of β-AA 
administration on concentrations of glucose may represent the initial signal for target tissues, 
ultimately inducing changes in nutrient repartitioning, and body composition (Blum and 
Flueckiger, 1988).  
Cattle fed β-AA had initial increases in lactate concentration, but effects diminished with 
chronic administration. Lactate is produced in cells that have high demand for glucose 
utilization. During glycolysis, glucose is broken down to produce pyruvate. When intracellular 
concentrations of pyruvate become elevated it is enzymatically converted to lactate (Kravitz, 
2005). Blum and Flueckiger (1988) fed P-5369 and Q-2636 to calves through milk replacer and 
observed an increase in concentrations of lactate up to 10 h after administration (P < 0.05) of 
either β-AA. In agreement, Zimmerli and Blum (1990) observed a postprandial increase in 
lactate (P < 0.05) on d 1 of administration of T-3660 and P-5369 to calves, but no further 
changes in following sampling days. These results coincide with results of plasma glucose, with 
an initial rise in glucose suggesting initial mobilization of glucose caused by β-AA treatment 
thus inducing an initial increase in lactate. When homeostatic mechanisms return glucose to 
normal levels, normal concentrations of lactate also are restored. 
Plasma urea nitrogen (PUN) and blood urea nitrogen (BUN) concentrations commonly 
are decreased in cattle fed β-AA. Urea is produced in the liver in response to excess nitrogen 
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intake or as a result of tissue protein catabolism, thus making PUN and BUN concentrations 
useful as indicators of protein turnover. Ricks et al. (1984) reported a decrease (P < 0.05) in 
BUN concentration in steers fed 500 mg/d clenbuterol compared to untreated steers. In 
agreement, Quirke et al. (1988) observed linear decrease in blood PUN concentration (P < 0.001) 
after steers were fed 8.25, 12.38, or 16.50 mg/kg diet DM cimaterol compared to control steers. 
Chikhou et al. (1991b) observed a decrease in PUN concentration on d 1 (P < 0.05), but 
concentrations on d 13 and 20 were not different than control steers with administration of 0.09 
mg/kg BW cimaterol. Conversely, Eisemann et al. (1988) fed 8 mg/d clenbuterol to steers, and 
observed no change (P > 0.05) in PUN concentration. Plasma urea nitrogen was numerically 
lower than control steers; however, the amount of clenbuterol fed may not have been sufficient to 
cause a significant difference. Similarly, Walker et al. (2007) observed no change for PUN 
concentration (P > 0.05) when 200 mg/d ractopamine was fed to steers; however, Walker et al. 
(2010) demonstrated ractopamine had a tendency to decrease PUN concentration (P = 0.06). 
Although not all studies observed significant decreases in urea nitrogen concentrations, 
numerical differences have been observed, which may be indicative of decreased protein 
degradation and/or increased protein synthesis (Mersmann, 1998).  
 Endocrine System 
Due to the vast abundance of β-AR located throughout the body, circulating hormones 
that may influence growth have been analyzed in an attempt to identify indirect mechanisms of 
action. Studies performed to determine indirect effects of β-AA have yielded conflicting results.  
Somatotropin causes the release of somatomedin, which ultimately mediates growth. 
Beermann et al. (1987) observed increased concentrations of somatotropin by wk 6 of 
administration (P < 0.01), but concentrations were not different wk 12 (P > 0.05) when cimaterol 
was fed to lambs. In contrast, Quirke et al. (1988) observed blood concentrations of GH were not 
different (P > 0.05) among steers treated with 0, 8.25, 12.38, or 16.5 mg/kg cimaterol. Similarly, 
Dawson et al. (1993) demonstrated that addition of cimaterol to diets of steers for 23 wk caused 
no differences in concentration of GH (P > 0.01) between treatments. Zimmerli and Blum (1990) 
observed an initial decrease in GH on d 0 for calves treated with  P-5369 or T-3660 (P < 0.05) 
compared to control calves, but no changes were observed on subsequent sampling days (P > 
0.05). This may be indicative of differences in the β-AA primary target receptor for which 
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binding occurs. Chikhou et al. (1991b) observed a similar acute decrease in GH concentration for 
steers 8 h after administration of cimaterol; however, chronic administration of cimaterol 
resulted in an increase in GH concentration when compared to untreated cattle. Beta agonists can 
acutely inhibit release of GH, but the mechanism responsible is not understood. It has been 
suggested that chronic administration of β-AA may cause desensitization in the β-receptors of 
the hypothalamic-peptidergic neurons thereby decreasing somatostatin secretion which regulates 
GH secretion (Chikhou et al., 1991b).  
Insulin-like growth factor 1 plays an important role in growth of developing animals due 
to its impact on cell growth, proliferation, and metabolism (Micke et al., 2010). Beermann et al. 
(1987) observed lower (P < 0.01) IGF-1 concentrations in lambs treated with cimaterol compared 
to their control counterparts. Similarly, Chikhou et al. (1991b) observed concentration of IGF-1 
decreased with chronic administration of cimaterol to steers. Walker et al. (2007) observed a 
tendency (P = 0.10) to decrease serum IGF-1 concentrations with addition of ractopamine. On 
the contrary, Winterholler et al. (2007) observed no difference (P > 0.05) in IGF-1 concentration 
in steers fed ractopamine compared to control animals. The authors suggested ractopamine may 
have an effect on IGF-binding protein (IGFBP) concentrations, which may account for 
differences observed among studies. Walker et al. (2010) reported a response to ractopamine, in 
which they found a difference between steers and heifers for IGF-1 concentration. Heifers had 
decreased concentration of IGF-1 d 14 and 28. Steers had decreased concentrations on day 14, 
but by day 28 ractopamine treated steers had greater concentrations of IGF-1 than their control 
counterparts. The authors suggested this may be in response to ractopamine having a direct effect 
on the liver, or it may alter IGF-1 clearance from the blood by affecting IGFBP. Contradicting 
these results, Quirke et al. (1988) found blood concentrations of IGF-1 were not different (P > 
0.05) for steers treated with 0, 8.25, 12.38, or 16.5 mg/kg cimaterol. Likewise, Zimmerli and 
Blum (1990) observed concentrations of IGF-1 were not different (P > 0.05) when calves were 
treated with P-5369 or T-3660 compared to control calves. Dawson et al. (1993) demonstrated 
that addition of cimaterol to diets of steers for 23 wk resulted in no difference in concentration of 
IGF-1 (P > 0.01) between treatments. Most of the circulating concentration of IGF-1 was thought 
to be released from the liver, therefore decreased concentrations of IGF-1 in steers administered 
β-AA may be due to the effect of β-AA on hepatic IGF-1 synthesis (Walker et al., 2007). 
Amount of β-AA administered may have contributed the differences among studies. 
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 Variable responses have been observed for insulin concentrations in livestock fed β-AA, 
while differences in glucagon concentration were not different between treated and untreated 
animals. Insulin and glucagon are hormones secreted by the pancreas, and work together to 
maintain glucose homeostasis in blood. Insulin is secreted when blood glucose levels are too 
high, whereas glucagon is secreted when blood glucose is low. Beermann et al. (1987) observed 
that insulin concentrations were decreased wk 6 and 12 (P < 0.01) after cimaterol feeding to 
lambs. Walker et al. (2007) observed a tendency (P = 0.10) for decreased insulin concentrations 
with addition of ractopamine. Conversely, Blum and Flueckiger (1988) observed, with acute 
administration of Q-2636 and P-5369 to calves, increased (P < 0.05) insulin concentrations up to 
6 h after administration. Furthermore, Zimmerli and Blum, 1990 observed increased insulin 
concentrations (P < 0.05) with addition of T-3660, but insulin concentrations were not different 
(P > 0.05) with administration of P-5369 compared to control calves, indicating potential 
differences in β-AR affected. Chikhou et al. (1991b) fed cimaterol to steers, and also observed 
increased insulin concentrations on d 1 (P < 0.05), but on d 13 and 20 the steers administered 
cimaterol had insulin concentrations similar to control steers. Lower insulin concentrations may 
be due to direct effects on the pancreas, as β-AA may stimulate both alpha and beta receptors 
(Beermann et al., 1987). The differences observed between studies for response of insulin may 
reflect differences in primary target receptors of the β-AA administered.  Although insulin 
concentration was observed to have variable responses with β-AA administration, Blum and 
Flueckiger (1988) observed no difference for glucagon concentration in calves treated with Q-
2636 or P-5369 (P > 0.05) compared to control calves. These results may reflect the differences 
in β-receptor density on the cells responsible for release of glucogon when compared to β-
receptors located on cells that secrete insulin.  
Triiodothyronine (T3) and thyroxine (T4) are hormones secreted by the thyroid gland 
affecting many processes in the body including, growth, heart rate, and cellular metabolism, and 
have been observed to be decreased or un-affected by β-AA treatment. Blum and Flueckiger 
(1988) observed concentrations of T3 were not different (P > 0.05) after Q-2636 or P-5369 
administration compared to control calves. Similarly, Zimmerli and Blum (1990) noted that T3, 
and T4 concentrations were unchanged (P > 0.05) after treatment with T-3660 or P-5369. 
Chikhou et al. (1991b) also observed no effect on T3 or T4 (P > 0.05) when steers were fed 
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cimaterol. Conversely, Fiems et al. 1989 observed decreased concentrations of T3 (P < 0.05) 
when cimaterol was administered to Belgian White-blue bulls for 84 and 196 d compared to 
control bulls, and decreased (P < 0.05) T4 concentrations after 28 and 84 d administration 
compared to controls.  The bulls in the experiment by Fiems et al. were genetically predisposed 
to heavy muscling, which may partially explain the difference in T3 and T4 concentration, when 
compared to other experiments; however, other experiments would suggest β-AA treatment does 
not affect thyroid gland secretions of T3 and T4. 
Acute effects of β-AA on hormone concentrations are no doubt evident; however tissues 
may become desensitized to β-AA, and effects may be attenuated with chronic exposure. These 
observations support the contention that indirect effects of the endocrine system may play a 
lesser role in explaining the growth response observed with β-AA administration. Additionally, 
inconsistent results observed in response to β-AA treatment would also suggest the hormones 
analyzed may not constitute important mechanisms by which β-AA exert their effect (Moody et 
al., 2000). A study  by Byrem et al. (1998), in which cimaterol was administered to steers 
through direct hindlimb infusion, showed an increase in muscle protein accretion, suggesting a 
direct response rather than indirect effect of β-AA (Moody et al., 2000).  
 Skeletal Muscle  
 A common observation with administration of β-AA is an increase in skeletal muscle 
mass in proportion to mass of adipose tissue. Figure 1.3 illustrates difference between loin eye 
sizes from the 12
th
 rib face of treated versus non-treated steers. The process by which nutrients 
are shifted to the tissues with greatest priority is under homeorrhetic control (Anderson et al., 
1991). The nutrient shift is accomplished by binding of β-AA with β-receptors in the arteries and 
veins, which increases blood flow to skeletal muscle in cattle and sheep. Increased blood flow 
may increase nutrient transport to skeletal muscle to accommodate increases in protein synthesis 
and resulting hypertrophy of muscle tissue in livestock (Mersmann, 1998). Beta adrenoceptors in 
skeletal muscle were reviewed by Kim and Sainz (1992), who noted that the primary receptor 
found in skeletal muscle is the β2-subtype (Kim and Sainz, 1992). The mechanism by which β-
AA exert their effect on skeletal muscle is less clear for livestock species (Moody et al., 2000), 
as studies are inconclusive. This lack of congruence among published studies may be due to 
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differences in animal species, β-AA used, dosage, and (or) duration of treatment. Moody et al. 
(2000) hypothesized that protein synthesis is enhanced and/or protein degradation is inhibited by 
treatment with β2-agonists cimaterol, clenbuterol, and L644,969, whereas the β1-agonist 
ractopamine affects only protein synthesis.  
Addition of β-AA to diets of ruminants has increased carcass weight, live weight, or 
both. Yang and McElligott (1989) described the response to β-AA in skeletal muscle as being 
hypertrophic rather than hyperplastic. Mice fed clenbuterol had reduced muscle wasting when 
fed a nutritionally poor diet compared to mice without clenbuterol, and atrophy was attenuated 
when denervated or suspended rat skeletal muscle was evaluated (Kim and Sainz, 1992).  
Beta agonist administration also influences fiber type and size. Beermann (2002) 
described the increase in muscle mass as being attributable to hypertrophy of type II muscle 
fibers. Type II fibers (fast-contracting, mixed glycolytic-oxidative) of lambs were reported to 
consistently increase in cross sectional-area, whereas type I fibers (slow contracting oxidative) 
were less affected (Yang and McElligott, 1989). Beermann et al. (1987) performed a study 
feeding cimaterol to lambs. The biceps femoris, semitendinosis, and semimembranosis in treated 
lambs were heavier after 12 wk of administration (P < 0.01) compared to those of non-treated 
lambs. Beermann et al. (1987) attributed the heavier muscle weights to hypertrophy of both type 
I and type II fibers. Additionally, Beermann et al. (1987) observed a decrease in percentage of 
type I fibers throughout the 12 wk experimentation period for all 3 muscle types. Distribution of 
fiber type also was notably different among treatments; the largest fibers were 35% greater in 
cimaterol treated lambs compared to control lambs (Beermann et al., 1987). Kellermeier et al. 
(2009) performed a study in which zilpaterol was administered to steers to evaluate effects on 
yield characteristics and tenderness, and observed a 5.87% increase (P < 0.001) in longissimus 
muscle fiber diameter in steers treated with zilpaterol compared to control steers. Furthermore, 
Kim et al. (1987) performed a study feeding cimaterol to lambs, and observed a 50% increase in 
(P < 0.01) cross-sectional areas of type II fibers in the longissimus dorsi and semitendinosus, but 
not in any other cut of meat. Additionally, there were no differences (P > 0.05) in cross-sectional 
area of type I fibers; indicating increases in muscle mass were due to hypertrophy of type II 
muscle fibers. Clearly, muscle hypertrophy occurred in β-AA treated animals. 
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Ractopamine is one of two β-AA approved for use in beef cattle in the United States. 
Cull beef cows treated with ractopamine had increased (P < 0.05) fiber diameter and cross-
sectional area of type I fibers; however, type II fiber diameter and cross-sectional area were 
unaffected (P > 0.05) by addition of ractopamine (Gonzalez et al., 2007). Ractopamine is 
primarily a β1-agonist, which could have a different effect on fiber size when compared to β2-
agonists. Contradicting previous work, Gonzalez et al. (2009) fed steers ractopamine and found 
no differences (P > 0.05) in cross-section area of type I or type II fibers in 6 different muscles, 
but did observe a shift from type I to type II fibers (P < 0.05) in the adductor, gracilis, 
longissimus lumborum, rectus femoris, and vastus lateralis. Discrepancies between studies may 
be due to age of animals tested, as cull cows tend to have fewer type II fibers compared to young 
animals. Differences observed among muscle types are attributable to density of β-receptors (β1 
vs. β2 vs. β3) as well as distribution of type I and type II muscle fibers (Kim and Sainz, 1992). 
Depending on the β-AA used, type I fibers may or may not be affected by β-AA treatment. 
Mersmann (1998) described the increase in skeletal muscle as being due to increases in 
protein synthesis and decreased protein degradation. Due to the difficulty with measuring protein 
degradation, protease activity was evaluated. Protease activity decreased when β-AA was 
administered, suggesting decreased protein degradation (Mersmann, 1998). Wheeler and 
Koohmaraie (1992) calculated fractional degradation rates of myofibrillar proteins to be lower (P 
< 0.05) after 3 wk and fractional accretion rates to be greater (P < 0.05) in steers treated with 
L644,969 suggesting β-AA administration decreases protein turnover. 
When carcass composition is evaluated, response to β-AA most frequently is 
characterized by increased carcass muscle mass and decreased carcass adipose tissue; however, 
different β-AA have different effects. Ricks et al. (1984) noted REA at the 12th rib face was 11 
and 16% greater, and back fat decreased 35 and 42% when steers were fed 10 or 500 mg/d of 
clenbuterol, respectively. Additionally, clenbuterol treated steers had more carcass protein and 
less fat than their control counterparts. Steers also had more water content in muscle than control 
animals. In agreement, Quirke et al. (1988) administered 33, 49.5, 66 mg/d cimaterol to steers, 
and observed a linear and quadratic decrease in percent fat (P < 0.001) with steers treated with 
66 mg/d having the lowest percent fat, and a linear and quadratic increase in percent lean tissue 
(P < 0.001) with 66 mg/d having the highest percent lean tissue. Additionally, percent moisture 
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and protein increased linearly in response to cimaterol (P < 0.01). L644,969 was administered to 
Friesian steers at rates of 0, 0.25, 1 or 4 mg/kg BW by Moloney et al. (1990), who observed 
linear and quadratic increase in percent lean tissue (P < 0.001) with steers fed 4 mg/kg BW 
having the greatest amount of percent lean tissue, and control steers having the least amount of 
percent lean tissue. A linear and quadratic decrease in percent fat (P < 0.001) was observed with 
steers fed 4 mg/kg containing the least amount of carcass fat, and control steers had the greatest 
amount of carcass fat. Steers fed 4 mg/kg had the greatest lean:fat ratio (P < 0.001) in the M. 
longissimus compared to the other treatments. Additionally, percent protein had a quadratic 
effect (P < 0.01) with steers fed 1 mg/kg having the greatest percent carcass protein. Percent 
carcass ash increased linearly (P < 0.05), and a linear and quadratic effect was observed for 
percent fat with 1 mg/kg having the lowest percent carcass fat (P < 0.01), and percent carcass 
moisture was unaffected by treatment of L644,969 compared to untreated steers (Moloney et al., 
1990). In agreement, Wheeler and Koohmaraie (1992) observed a 21% increase in 
semitendinosis muscle weight (P < 0.05), and total carcass protein was increased 23.5% (P < 
0.05) with addition of L644,969 to diets of steers. In general, carcass composition is altered with an 
increase in amount of muscle mass, and decreased amount of carcass fat. 
Caine and Mathison (1992) fed cimaterol to lambs at rates of 1.1or 2.2 × maintenance. 
Fat concentration (g/g tissue) was lower in the psoas major muscle and semitendinosus muscle 
(P < 0.01), and tended to be lower in the gastrocnemius muscle (P = 0.09). Contrary to the 
previous studies with cattle, Caine and Matheson (1992) observed no difference (P > 0.05) in the 
amount of protein in gastrocnemius or semitendinosus muscles; however, protein:fat ratio in the 
gastrocnemius, psoas major, and semitendinosus muscles increased (P < 0.01). The differences 
observed may reflect receptor density in the muscles evaluated, indicating muscle types have 
different β receptor densities. 
Zilpaterol hydrochloride was approved for use in the United States in 2006, and also 
affects body composition of cattle. Avendaño-Reyes et al. (2006) performed a study in which 
zilpaterol was administered to steers. They observed no differences (P > 0.05) in percent lean, 
bone, or fat in treated steer carcasses compared to control animals. Conversely, Leheska et al. 
(2009) observed an increase in carcass muscle deposition in both steer and heifer carcasses (P < 
0.01) with zilpaterol administration, but percent fat and moisture content were unaffected (P > 
0.05) by treatment. Percent bone was decreased (P = 0.02) in heifers, but not different in steer 
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carcasses (P > 0.10), and percent carcass ash was unaffected (P > 0.05) by β-AA treatment. The 
authors concluded that effects observed in their study, compared to those reported by Avendaño-
Reyes et al. (2006) may have been due to the lower dose of zilpaterol hydrochloride administered 
(60 mg/d) by Avendaño-Reyes et al. or differences in genetic make-up of the cattle. Results by 
Shook et al. (2009) are in agreement with those of Leheska et al. (2009), demonstrating an 
increase in percent lean tissue (P < 0.05), no change in percent carcass fat (P > 0.05) , and a 
decrease in percent bone (P < 0.05) with zilpaterol hydrochloride administration. Hilton et al. 
(2009) observed a decrease in estimated carcass fat (P < 0.01) and an increase in estimated 
carcass moisture and protein (P < 0.01) with zilpaterol hydrochloride administration; however, 
the decrease in carcass fat was not as pronounced as seen with cimaterol or clenbuterol 
administration. Table 1.2 summarizes effects of β-AA on cattle growth and carcass composition.   
The calpain proteolytic system, which is partly responsible for post-mortem tenderization 
of meat, also is affected by β-AA. Calpains play an important role in turnover of myofibrillar 
proteins in live animals and in post-mortem aging (Koohmaraie et al., 1991). Administration of 
L644,969 to lambs increased total extractable µ-calpain and calpastatin by 24.6 and 62.8%, 
respectively, at d 0 of storage, and were 89.2 and 227.2%  greater than control lambs on d 7 
(Koohmaraie et al., 1991). The increase in calpastatin, which inhibits calpains, supports the 
argument β-AA interfere with muscle protein degradation. Contrary to the findings by 
Koohmaraie et al. (1991), Wheeler and Koohmaraie (1992) administered L644,969 to steers, and 
observed that µ-calpain and calpastatin activity decreased over a 7-d aging period for both 
treated and non-treated animals (P < 0.05). The authors also found that total activity of 
calpastatin in β-AA treated animals increased (P < 0.05) in comparison to their control 
counterparts indicative of reduced protein degradation in treated steers. Post-mortem proteolysis 
and tenderization were reduced (P < 0.05) in steers fed L644,969, as shear force values did not vary 
from d 1 to 14 postmortem (Wheeler and Koohmaraie, 1992). The authors concluded that 
inhibition of calpain activity by increased calpastatin activity in β-AA fed steers was responsible 
for decreases in post-mortem proteolysis. Hilton et al. (2009) analyzed the calpain proteolytic 
system with administration of zilpaterol, and found that calpastatin, µ-, and m-calpain were 
unaffected (P > 0.05) by zilpaterol supplementation. The authors attributed the lack of effect to 
the possibility of zilpaterol having a greater influence on protein accretion rather than decreasing 
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protein degradation. Beta agonists cause different responses in the proteolytic system indicating 
differences in target receptor activity.   
 Adipose Tissue 
Administration of β-AA has been noted to decrease adipose tissue content of carcasses. 
Yang and McElligott (1989) suggested that decreased body fat may be a result of increased fat 
mobilization, decreased fat synthesis, or both. They proffered that binding of β-AA to adipose 
tissue β-receptors results in a cascade of events that lead to activation of lipase, and resulting 
triacylglycerol hydrolysis (Yang and McElliogott, 1989). Lipogenic enzymes were measured in 
vitro and activities of enzymes were decreased in subcutaneous adipose tissue, but not in 
intramuscular or perirenal adipose tissue (Yang and McElligott, 1989). This observation may 
help to explain inconsistencies observed in carcass composition measurements described 
previously in this review. In vivo measurements are commonly evaluated by measuring 
concentrations of NEFA or glycerol in blood (Yang and McElligott, 1989; Mersmann 2002). 
Administration of β-AA caused NEFA levels to rise in treated animals, which would suggest 
activation of the adipocyte lipolytic system (Beermann et al., 1987; Blum and Flueckiger, 1988; 
Chikhou et al., 1991). After the acute response to β-AA administration, responses decrease with 
chronic exposure (Eisemann et al., 1988; Zimmerli and Blum, 1990; Chikhou et al., 1991).  
 In reviewing studies regarding carcass composition, most reported decreases in amount of 
carcass fat; however, there are a few research trials in which carcass fat was not affected with the 
addition of β-AA (Avendaño-Reyes et al., 2006; Leheska et al., 2009; Shook et al., 2009). This 
may be explained by differences in study design. In earlier experiments the β-AA was fed to the 
animals or not, and then carcass composition was compared among treatments. This type of 
design has migrated to comparisons in which cattle fed β-AA were fed to large carcass weights, 
but similar fatness. Studies in which zilpaterol was administered to livestock are inconsistent 
with regards to its effect on adipose tissue as compared to studies in which cimaterol or 
clenbuterol are administered. An explanation for this observation may be that zilpaterol 
stimulates protein accretion more so than lipolysis, thus increasing carcass muscle as opposed to 
mobilizing body fat (Mersmann, 2002). Furthermore, differences in study design, such as genetic 
make-up of animals tested may be a cause of discrepancies between studies (Mersmann, 1998). 
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Chronic exposure to β-AA may cause inactivation or removal of the β-receptor from the cell 
surface quicker in adipose tissue when compared to skeletal muscle, thus attenuating the 
response in adipose tissue (Mersmann, 1998). Miller et al. (2012) performed an in vitro trial 
treating freshly obtained adipose tissue with 4 different concentrations of zilpaterol, and 
concluded that effects of zilpaterol on de novo fatty acid synthesis were minimal, and that 
changes in carcass fat are likely caused by redirection of nutrients from adipose tissue fatty acid 
biosynthesis to muscle accretion.  
 Conclusion 
Although β-AA have been researched extensively in the livestock industry for their 
effects on carcass composition, it is clear that these compounds influence a broad range of body 
systems. Beta agonists can cause an initial rise in respiration rate. Inconsistent results were 
observed when analyzing the smooth muscle of the digestive tract and microbial fermentation. 
Hormonal response to β-AA treatment also is not consistent between studies. Variable responses 
are to be expected when comparing responses to different β-AA because a single agonist has not 
been tailored to all species (Mersmann, 2002). Many factors can cause inconsistent results 
demonstrated in this review. These factors include species of animal, age, dose of β-AA, 
duration of treatment, diet, genetics, and possible even animal weight; all of which make it very 
difficult to quantify mechanisms of action of β-AA in general.   
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Table 1.1: Radioligands for β-adrenergic receptors1 
Radioligand Specificity 
Antagonist 
   l-[
3
H]dihydroalprenolol ß1 = ß2 
   dl-[
3
H]propranolol ß1 = ß2 
   l-[
3
H]propranolol ß1 = ß2 
   dl-[
3
H]carazolol ß1 = ß2 
   l-[
3
H]carazolol ß1 = ß2 
   l-[
3
H]bupranolol ß1 = ß2 
Agonists 
   dl-[
3
H]hydroxybenzylisoproterenol ß1 < ß2 
   l-[
3
H]epinephrine ß1 < ß2 
   l-[
3
H]norepinephrine ß1 > ß2 
   dl-[
3
H]isoproterenol ß1 = ß2 
1
Antagonist radioligands are used to study adrenergic receptor abundance and properties, and 
agonist radioligands for researching mechanisms of action of agonist attachment to adrenergic 
receptors. Table adapted from Stiles et al. 1984.
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Figure 1.1: Structure of naturally occurring catecholamines and common beta agonists 
                          
 Epinephrine                                                           Norepinephrine 
                            
Cimaterol                                                               Clenbuterol 
                           
Ractopamine Hydrochloride                                    Zilpaterol Hydrochloride 
Figures from pubchem.ncbi.nlm.nih.gov
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Table 1.2: Effects of beta-agonists on carcass composition of growing cattle 
 Control values and proportional responses (%)  
 Carcass composition  
Treatment 
Dose (mg/kg) 
Treatment 
period (d) ADG
a
 (g/d) F:G
b 
Protein Lipid Reference 
Clenbuterol       
     0 98 1007 11.83 15.4%
c 
35.2%
c 
Ricks et al. 
(1984)      10  -8 -2.1 +13* -20* 
     500  -20 0 +14* -30*  
Cimaterol       
     0 91 816 11.7 203 kg
d 
75.1 kg
d 
Hanrahan 
et al. 
(1986) 
     3.5  +18* -23.5* +24.5* -28.1* 
     5.1  +30.4* -30.6* +30.0* -30.4* 
     7   +6.0 -8.2 +27.6* -35.0*  
L-644,969       
     0 84 780 10.2 60.4%
e 
21.4%
e 
Moloney et 
al. (1990)      0.25  +10 -14.0 +3 -14.5* 
     1.0  +16 -19.6 +4.5 -29* 
     4.0  +10 -23.4 +15.6* -35*  
Ractopamine       
     0 56 1430 5.37 13.2%
c 
42.6%
c 
Anderson 
et al. 
(1991) 
     20  +7.7 -8.2* +4.5 -4.9 
     40  +7.7 -8.6* +6* -4.7 
     60  +9 -10.6* +7.3* -8.7*  
     80  +16.8* -17.7* +9.8* -9.8*  
 Table adapted from Beermann (1994) 
a
Average daily live-weight gain. 
b
kg feed per kg live-weight gain. 
c
Chemical composition of 9
th
 to 11
th
 rib section. 
d
Total carcass muscle and adipose tissue weights based on half carcass physical dissection. 
e
Percentage of physically dissected skeletal muscle and adipose from carcass side. 
*P < 0.05. 
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Figure 1.2: Twelfth rib face of steers treated with and without ractopamine.  
The loin on the right came from a steer that had been treated with ractopamine for 42 d prior to 
harvest, and the loin on the left came from an untreated steer.  
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Abstract 
Effects of zilpaterol hydrochloride (ZH) on blood metabolites and carcass traits were 
evaluated in crossbred finishing steers (n=18, BW 639 kg ± 12.69) that were stratified by BW 
and randomly assigned, within strata (block), to receive 0 (control) or 8.33 mg/kg diet DM ZH. 
Cattle were fed once daily ad libitum in individual feeding pens (9 pens/treatment). ZH was fed 
23 d and withdrawn 3 d before harvest. Blood samples and measures of BW were taken on d 0, 
7, 14, and 21. Concentrations of beta-hydroxybutyrate (BHB), glucose, and lactate were 
determined for whole blood, and NEFA, urea nitrogen (PUN), and long-chain fatty acids (LCFA) 
concentrations were analyzed from plasma. Adipose tissue samples (approximately 20 g) from 
subcutaneous fat covering the lumbar vertebrae were collected after 48-h of refrigeration and 
analyzed for LCFA profiles. Feeding ZH decreased DMI by 8% (P < 0.10), but did not impact 
live BW gain or efficiency (P > 0.10). Addition of ZH resulted in greater HCW, dressing 
percentage, and LM area (P < 0.10), but did not influence other carcass traits (P > 0.10). ZH 
decreased glucose and PUN concentrations (P < 0.10). A ZH × d interaction also was observed 
(P < 0.10) for PUN concentrations. Concentration of PUN increased over time in control cattle, 
but decreased in cattle receiving ZH. Nonesterified fatty acids, BHB, plasma glucose, whole 
blood and plasma lactate concentrations were unaffected by ZH (P > 0.10). Zilpaterol 
hydrochloride increased plasma concentrations of elaidic, vaccenic, and docosapentaenoic acids 
(P < 0.10), but LCFA concentrations of adipose tissue were unaffected (P > 0.10), suggesting no 
preferential oxidation of specific fatty acids. ZH supplementation decreased plasma nitrogen 
concentration to accommodate increased muscle accretion at the expense of adipose tissue. 
Key words; glucose, plasma urea nitrogen, zilpaterol hydrochloride  
 Introduction 
Synthetic β-adrenergic agonists (βAA), which are similar in structure to the naturally 
occurring catecholamines norepinephrine and epinephrine, are known to induce accretion of 
skeletal muscle at the expense of adipose tissue (Mersmann, 1998). Plasma urea nitrogen (PUN) 
is a measurement associated with nitrogen metabolism and has been observed to decrease in 
plasma with clenbuterol and cimaterol administration (Ricks et al., 1984 and Byrem et al., 1996). 
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Additionally, blood metabolites associated with carbohydrate and lipid metabolism (i.e. lactate, 
NEFA) have been shown to increase in response to cimaterol and clenbuterol feeding (Eisemann 
et al., 1988 and Chikhou et al., 1991), while plasma glucose concentrations have been observed 
to either increase or decrease during administration of P 5369, Q 2636, or cimaterol (Blum and 
Flueckiger, 1988; Quirke et al., 1988). Zilpaterol hydrochloride (ZH), a β2-AA merchandized 
under the trade name, Zilmax (Merck Animal Health, Millsboro, DE), has been reported to 
improve feed efficiency, ADG, dressing percentage, HCW, and LM area (Montgomery at al., 
2009; Plascencia et al., 2008). Hilton et al. (2009) reported decreases in USDA yield grade and 
total carcass fat with ZH use. Our interest was in assessing the underlying changes in metabolism 
with addition of ZH to diets of finishing cattle. We hypothesized blood components related to 
muscle growth (i.e. glucose, and PUN) will be decreased to accommodate the increase in muscle 
mass, while blood components related to lipid metabolism (i.e. NEFA, and β-hydroxybutyrate, 
lactate) will be increased in plasma. The objectives of our study were to evaluate the effects of 
ZH on blood concentrations of glucose, lactate, NEFA, β-hydroxybutyrate (BHB), and plasma 
urea nitrogen (PUN), and to assess changes in long chain fatty acid (LCFA) profiles of plasma 
and adipose tissue.  
 Materials and Methods 
 Animals and sampling: 
Protocols and procedures followed in this study were approved by the Kansas State 
University Institutional Animal Care and Use Committee.  
The study was conducted at the Kansas State University Beef Cattle Research Center, 
located in Manhattan, KS. Eighteen crossbred steers (initial BW 614 kg ± 12.69) were stratified 
by initial body weight, and randomly allocated, within strata, to two treatment groups. Cattle 
were randomly assigned to individual, partially covered feeding pens equipped with concrete 
floors, fence line feed bunks, automatic water fountains (9 pens/treatment), and were fed once 
daily ad libitum. Treatments consisted of diets with or without ZH. Zilpaterol hydrochloride was 
fed at a rate of 8.33 mg/kg of diet DM beginning 26 d before the end of the study and withdrawn 
from the diet 3 d prior to harvest. Diet composition is presented in table 2.1. Body weights were 
measured for each steer at 7-d intervals, and again on the d of harvest. Blood was drawn from 
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each steer via jugular venipuncture prior to feeding on d 0, 7, 14, and 21. Blood was collected in 
two 6-mL EDTA-containing vacutainer tubes/animal (Becton Dickinson and Company, Franklin 
Lakes, NJ). The first tube was placed on ice and transported immediately (approximately 10 min) 
to the Pre-Harvest Food Safety Laboratory located at Kansas State University’s main campus, 
and analyzed to determine whole blood concentrations of glucose and lactate. The second blood 
sample was immediately placed on ice then centrifuged within 20 min of sampling at 2,000 × g 
for 10 min to recover plasma. Plasma was transferred to 5-mL plastic tubes, capped, and stored 
at -20ºC until analyzed for concentrations of plasma urea nitrogen (PUN), NEFA, glucose, and 
lactate. Additionally, fatty acid profiles of plasma were measured for each steer at each time 
point. Finally, BHB was measured using fresh blood by allowing a small amount of blood to 
drop onto test strips prior to removal of the needle from the jugular vein. Concentrations of BHB 
were analyzed using the Precision Xtra Advanced Diabetes Management System (Abbott 
Diabetes Care Inc., Alameda, CA). Precision Xtra Blood β-ketone test strips (Abbott Diabetes 
Care Inc., Alameda, CA) were required for BHB concentration analysis. The Precision Xtra was 
placed in ketone mode and blood was analyzed according to kit directions. Results for BHB were 
provided within 10 s after initiation of the test.  
Feed intakes were monitored daily, and unconsumed feed was removed from the bunk, 
weighed, and dried at 55ºC for 48 h at weekly intervals or as needed to determine actual feed 
intake. Feedstuffs were sampled weekly and analyzed for DM, starch, NDF, CP, S, and ether 
extract. Portions of ground samples of feedstuffs were dried in a forced air oven at 105°C 
overnight to determine DM (Undersander et al., 1993). Starch contents of feedstuffs were 
determined according to Herrera-Saldana and Huber (1989) with a Technicon Autoanalyzer III 
(SEAL Analytical, Mequon, WI). Determination of NDF was conducted using an ANKOM fiber 
analyzer (ANKOM Technology Corp., Fairport, NY) according to Van Soest et al. (1991).  Heat-
stable α-amylase (ANKOM Technology Corp) was added to remove residual starch from 
feedstuff samples. Determination of CP was accomplished by measuring N content with a LECO 
FP–2000 nitrogen analyzer (LECO Corp., St Joseph, MI) following AOAC (1995) official 
method 990.03. Ether extract analysis was performed according to AOAC (1995) official method 
920.39.  
Average daily gains were computed by subtracting initial shrunk live weight from shrunk 
final BW (gross BW × 0.96), and dividing by days on feed (DOF). Gain efficiencies were 
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computed by dividing ADG by DMI. Final BW (gross BW × 0.96) were determined immediately 
before cattle were shipped 451 km to a commercial abattoir in Holcomb, KS. Hot carcass weight 
and incidence and severity of liver abscesses were recorded the d of harvest. Liver abscesses 
were scored according to the Elanco scoring system (Liver Abscess Technical Information AI 
6288, Elanco Animal Health, Greenfield, IN): 0 = no abscesses, A
-
 = 1 or 2 small abscesses or 
abscess scars, A
0
 = 2 to 4 small, well-organized abscesses and A
+
 = 1 or more large or active 
abscesses with or without adhesions. USDA Yield Grade, USDA quality grade, marbling score, 
12
th
 rib fat thickness, loin-eye area, percent KPH, and incidence and severity of dark cutting beef 
were collected after carcasses were refrigerated for 48 h. Finally, a 20-g sample of subcutaneous 
adipose tissue was removed from fat covering the lumbar vertebrae on the left side of each 
carcass and placed on ice. Adipose samples were transported to Kansas State University and 
placed into a freezer at -20ºC until analyzed for composition of fatty acids (LCFA).  
 Chemical Analyses 
Glucose and lactate concentrations of both plasma and whole blood were analyzed in 
duplicate using the YSI 2300 STAT Plus Glucose and L-lactate Analyzer (YSI Inc., Yellow 
Springs, OH). Whole blood glucose and lactate were measured within 10 min after sampling. 
The HR Series NEFA-HR kit (Wako Diagnostics, Richmond, VA) was used for determination of 
NEFA concentrations in plasma. Samples were measured in duplicate with the Biotek 
PowerWave XS (Winoski, VT) using a wavelength of 550 nm. Plasma urea nitrogen 
concentration was determined according to procedures described by Marsh et al. (1965) using an 
Auto Analyzer II (Seal Analytical, Mequon, WI). 
 For analysis of plasma fatty acids, 500 µL of plasma were frozen and subsequently 
lyophilized overnight using the Labconco Freeze Dryer 5 (Labconco Corporation, Kansas City, 
MO). One milliliter of benzene containing internal standard 1,000 µg/mL methyl-C:13 was 
added to each tube. Samples were capped immediately and vortexed to dissolve the pellet. Four 
milliliters of BF3-methanol reagent (Supelco B1252; Sigma-Aldrich, St. Louis, MO) were added, 
tubes were recapped, mixed gently by inverting the tubes, then incubated at 60°C for 60 min. 
Samples were allowed to cool to room temperature, and 4 mL of distilled deionized water and 1 
mL hexane were then added. Tubes were recapped and vortexed. Samples were centrifuged at 
1,000 × g for 5 min, and supernatant was transferred (1 to 2 mL) to gas chromatography vials.  
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Determination of adipose tissue LCFA concentration was performed following the 
procedure described by Sukhija and Palmquist (1988). Concentrations of LCFA for both plasma 
and adipose tissue were analyzed using a Shimadzu Model GC-17A (Columbia, MD) gas 
chromatograph equipped with a Supelco SP-2560 capillary column (100 m X 0.25 mm X 0.20 
um film). Injection and detector temperatures were set at 260°C. Initial oven temperature was 
140°C, held 5 min, then increased at the rate of 4ºC/min to a final temperature of 240°C. Column 
flow rate was 1.1 mL/min, and nitrogen was used as the carrier gas. Supelco 37  FAME mix 
(Supelco # 47885-U; Sigma-Aldrich, St. Louis, MO) was used as the standard.  
 Statistical Analyses 
Blood metabolites and plasma LCFA were analyzed as repeated measures using the 
MIXED procedure of SAS version 9.1 (SAS Inst. Inc., Cary, NC). Animal was the experimental 
unit, and the model included fixed effects of ZH, d, and ZH × d. The random effects were block 
and block × ZH. Likewise, live performance and carcass traits were analyzed using the MIXED 
procedure where ZH was the fixed effect, and block and block × ZH were the random effects. 
The LSMEANS statement was used for means and standard error calculations, and the PDIFF 
option was used for separation of means. Means separations were declared significant at an α 
level ≤ 0.10 to accommodate the small number of experimental units. 
 Results and Discussion 
One animal from the control group was removed from the study due to respiratory 
disease. The steer began to display symptoms the second week of the study. 
 Live animal performance is presented in table 2.2. Zilpaterol hydrochloride 
supplementation did not affect final BW (P > 0.10). Observations of BW change have not been 
consistent among published studies. In agreement, Vasconcelos et al. (2008) and Holland et al. 
(2010) observed no difference (P > 0.10) in final BW with ZH administration when compared to 
un-treated cattle. Contradicting our results, Montgomery et al. (2009b) observed an increase (P = 
0.01) in final BW for ZH supplemented steers compared to steers receiving no ZH in a study 
observing effects of ZH in combination with monensin and tylosin. Additionally, Scramlin et al. 
(2010) performed a study that fed either ZH or ractopamine to cattle and compared growth 
performance and carcass responses. The authors observed an increase in final BW (P < 0.05) 
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with ZH supplementation when compared to control cattle. Differences between trials may be 
attributed to genetic differences in animals utilized as genetics can affect response to βAA 
treatment (Mersmann, 1998). 
Feeding ZH to steers decreased DMI by 8% (P = 0.03). Zilpaterol hydrochloride 
supplementation has been reported to either have no effect (P > 0.05) on DMI (Avendaño- Reyes 
et al., 2006; Plascencia et al., 2008; Parr et al., 2011), or, in agreement with our results, has been 
observed to cause a decrease (P < 0.05) in DMI (Montgomery et al., 2009b; Holland et al., 2010; 
Scramlin et al., 2010). Despite the decrease in DMI in the present study, neither ADG (P = 0.83) 
nor G:F (P = 0.56) were influenced by ZH supplementation. Contradicting our results, Elam et 
al. (2009) found a linear increase in ADG and G:F when comparing ZH supplementation for 0, 
20, 30, or 40 d. Other studies have also reported an increase in G:F with ZH supplementation 
when compared to un-treated cattle (Montgomery et al., 2009a; Avendaño- Reyes et al., 2006; 
Scramlin et al., 2010). Parr et al. (2011) performed a study that compared responses to anabolic 
implants Revalor-S and Revalor-XS with and without ZH. The authors observed an improvement 
in feed efficiency (P = 0.01) as well as an increase in ADG (P = 0.01) with ZH administration. 
Performance of steers in the present study may have been compromised by the weekly handling 
of the steers which could be a possible explanation for the lack of an effect on ADG and feed 
efficiency. Furthermore, the low statistical power of this study may also be a reason no 
differences were observed for ADG and G:F. 
The goal of this experiment was to evaluate blood components related to growth with ZH 
supplementation. Glucose is an important source of energy for mammalian cell function. There 
was a ZH × sampling d interaction (P = 0.06) for whole blood glucose; concentration decreased 
over time with addition of ZH; however, there was no ZH × sampling d interaction (P = 0.37), 
ZH (P = 0.52), or sampling d (P = 0.68) effects for plasma glucose concentration (table 2.3). The 
difference between whole blood and plasma glucose concentration may reflect the inaccuracy of 
attempting to measure whole blood glucose samples when the measuring device is not on site. 
The active cells in the blood samples used for whole blood analysis may affect the ability to 
measure glucose values when the cells are given the opportunity to continue to metabolize 
glucose during transportation. Additionally, Hasegawa and Townley (1983) performed a study to 
determine down-regulation of beta receptors in spleen and lung tissue, both of which were found 
to contain beta-adrenergic receptors. Zilpaterol hydrochloride supplementation may induce 
47 
 
secretion of stored red blood cells in the spleen through activation of beta-adrenergic receptors, 
thus increasing the amount of cells available to metabolize glucose. In agreement with our 
results, Ricks et al. (1984) performed a study in which they fed 0, 10, or 500 mg/d of clenbuterol 
for 98 d to steers. The authors found no difference (P > 0.05) in plasma glucose concentration in 
steers fed clenbuterol compared to steers fed a control diet without clenbuterol. Quirke et al. 
(1988) administered the β2-AA cimaterol to steers at rates of 0, 33, 49.5, or 66 mg/d. No effect 
(P > 0.05) on plasma glucose concentration was observed. Additionally, Beermann et al. (1987) 
performed a study using lambs which received 0 or 10 mg/kg cimaterol for 7 or 12 wk. The 
authors also observed no difference (P > 0.05) in plasma glucose concentration. Contradicting 
these results, Eisemann et al. (1988) performed a study in which steers were fed 8 mg/d of 
clenbuterol daily for 9 d. Blood samples were taken from steers on d 1 and 9. The authors 
observed an initial increase (P = 0.02) in glucose concentration; however, after d 9 of feeding, 
glucose concentrations were not different (P > 0.05). The authors suggested an initial increase in 
glucose rate of entry due to increased liver gluconeogenesis or glycogenolysis (Eisemann et al., 
1988). Results from Eisemann et al. (1988) would suggest there is an initial response in glucose 
metabolism due to βAA administration, but cells become quickly desensitized and the response 
is no longer observed. These results would explain why our data showed no difference in plasma 
glucose concentration as our first sampling time was 7 d after administration of ZH.  
Lactate is produced in cells that have high demand for glucose utilization. During 
glycolysis, glucose is broken down to produce pyruvate. As intracellular pyruvate concentration 
increases, 2 protons are absorbed, and lactate is produced enzymatically (Kravitz, 2005). We 
observed no ZH × sampling d interaction (P > 0.10) or effect of ZH (P > 0.10) for whole blood 
or plasma lactate, but an effect of sampling d (P < 0.10) was observed. Concentrations of whole 
blood and plasma lactate were lower on d 7, 14, and 21 when compared to d 0 (table 2.3). Blum 
and Flueckiger, (1988) fed P-5369 and Q-2636 to calves through milk replacer and observed an 
increase (P < 0.05) in concentrations of plasma lactate up to 10 h after administration of both β-
agonists compared to control calves. Additionally, Byrem et al. (1996) found when cimaterol 
was administered to steers through arterial infusion, circulating concentrations of lactate 
increased (P < 0.01) with increasing concentrations of cimaterol. Similar findings for lactate 
concentrations were reported for clenbuterol suggesting an increase of peripheral glycolysis 
(Eisemann et al., 1988). Differences between our study and those cited may be the age difference 
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of the animals. Steers in our study were older than those previously utilized for study. 
Additionally, ZH may initially affect the demand for glucose similar to other βAA by stimulating 
glycogenolysis (Blum and Flueckiger, 1988) and possibly glycolysis, thus indirectly increasing 
concentration of lactate in plasma initially. 
Decreased body fat is a common effect of βAA supplementation, and may be a 
consequence of increased fat mobilization, decreased lipogenic activity, or a combination of both 
(Yang and McElligott, 1989). Plasma NEFA concentration has been utilized as a blood 
parameter to estimate lipolysis as it exhibits a strong correlation to NEFA turnover (Beermann et 
al., 1987). In this study, no effects of ZH × sampling d interaction, ZH, or sampling d (P = 0.97; 
P = 0.25; P = 0.78, respectively) were observed for plasma NEFA concentrations in steers fed 
diets with and without ZH (table 2.3), which is in disagreement with previous research feeding 
other βAA. Beermann et al. (1987) observed a 60% increase (P < 0.01) in NEFA concentrations 
in lambs fed cimaterol, but the increased NEFA concentration was attributed to lambs being 
fasted 1 d prior to sampling. Quirke et al. (1988) administered 0, 33, 49.5, or 66 mg/d cimaterol 
to steers, and reported a quadratic increase (P < 0.05) in NEFA concentration. Steers fed 33 mg/d 
had NEFA concentrations lower than animals fed 0 mg/d cimaterol, and steers receiving 66 mg/d 
had the largest increase in NEFA concentration. Chikhou et al. (1991) performed a study using 
12 steers fed 0 or 0.09 mg/kg BW cimaterol for a period of 13 d. The authors observed an 
increase in plasma NEFA concentration (P < 0.05) on d 1 and 13 of sampling, which was 
attributed to increased lipolysis and reduced uptake of free fatty acids by adipose tissue in steers 
fed cimaterol. Byrem et al. (1996) administered cimaterol to steers through arterial infusion, and 
circulating concentrations of NEFA increased (P < 0.01). In a follow up study, Byrem et al. 
(1998) observed an initial increase in plasma NEFA concentration after 6 h (P < 0.05) of close-
arterial infusion of cimaterol, but after 24 h of infusion there was no difference (P > 0.05) in 
NEFA concentration compared to basal concentrations. The differences observed between the 
NEFA concentrations in our study and previous work may reflect physiological differences 
among animals, and the βAA utilized. Variable responses have been caused by use of different 
βAA because there has not been an individual βAA tailored to all species (Mersmann, 2002). 
Absorption rate, metabolism of the agonist by organs, and rate of excretion control the 
concentrations maintained in plasma and target organs (Mersmann, 2002). Moreover, fatty acid 
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synthesis and esterification of FFA into triacylglycerols both are inhibited by βAA. The decrease 
in lipogenesis with βAA administration would lead to decreased adipocyte hypertrophy, thereby 
decreasing fat deposition (Mersmann, 2002). Although not all βAA affect fat catabolism, there is 
proportionately less fat in carcasses due to increased skeletal muscle growth with βAA use. ZH 
may have greater impact on skeletal muscle growth than lipolysis, which could explain the 
relative absence of significant differences in blood parameters related to lipolysis.  
Beta-hydroxybutyrate is a ketone body produced from metabolism of NEFA by the liver, 
and usually is elevated in states of negative energy balance (Ospina et al., 2010). We observed 
no ZH × sampling d interaction (P = 0.97) for BHB concentration (table 2.3), and no effects of 
ZH supplementation or sampling d (P = 0.94; P = 0.74, respectively). Likewise, Eisemann et al. 
(1988) observed no changes (P > 0.10) in BHB concentration when clenbuterol was administered 
to cattle. Collectively, these results suggest cattle are able to metabolize BHB concentrations at 
rates sufficient to avoid accumulation within blood. Another explanation to the lack of effect on 
BHB concentration may be correlated to the lack of effect of ZH on lipolysis evident by no 
response in plasma NEFA concentration. 
Comparing PUN concentrations between treatments, there was a ZH × sampling d 
interaction (P = 0.06); cattle in the control and ZH treatments started with similar PUN 
concentrations, but cattle fed ZH had lower PUN concentration (P < 0.05) from d 7 to d 21 
(figure 2.1). An increase in nitrogen retention suggests nitrogen is being utilized more efficiently 
for muscle accretion. Decreases in PUN concentrations following ZH supplementation are 
consistent with observations in previous experiments with other β2-AA (Ricks et al., 1984; 
Eisemann et al., 1988; Quirke et al., 1988), which may reflect decreased protein catabolism in 
skeletal muscle with βAA supplementation. 
 A ZH × sampling d interaction (P < 0.10) was observed for plasma concentrations of 
elaidic (C18:1n9t), vaccenic (C18:1n7), and docosapentaenoic acids (C22:5n3). Additionally, an 
effect of d (P < 0.10) was observed for 9 of the analyzed fatty acids, and a tendency for a ZH × d 
interaction for total plasma fatty acid concentration (P = 0.14; summarized in table 2.4). 
Heneicosanoic acid (C21:0) was the only adipose tissue fatty acid (table 2.5) affected by ZH (P = 
0.005). We concluded ZH supplementation had a minor effect on adipose tissue LCFA 
concentration. Engeseth et al. (1992) performed a study feeding ractopamine to pigs harvested at 
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1, 2, 4, and 6 wk of feeding. The authors collected adipose tissue at each harvest date and 
analyzed fatty acid profiles. Animals receiving ractopamine had lower 18:0 (P < 0.05) and higher 
18:3 (P < 0.05) percentages after 4 wk of feeding, and a higher percentage of 18:2 fatty acid (P < 
0.01) after wk 6 of feeding. Similarly, Engeseth et al. (1992) concluded ractopamine had only a 
minor effect on fatty acid profiles of adipose tissue. The limited changes observed in LCFA 
profiles of plasma and adipose tissue suggests there is no preferential oxidation of any specific 
fatty acid with ZH supplementation. Again, the lack of an effect on lipolysis may contribute to 
the minimal effect on fatty acid concentration. 
Zilpaterol hydrochloride supplementation increased HCW by approximately 3% (P = 
0.02), dressed yield percent by 1.9% (P = 0.08), and LM area by 11.9% (P = 0.07; table 2.6). 
Marbling score and yield grade were numerically lower with ZH supplementation, but these 
differences were not significant (P = 0.12, P = 0.47, respectively). Animals in the present study 
were not affected by liver abscesses. Additionally, there were no differences (P > 0.10) between 
cattle fed diets with and without ZH with respect to USDA quality grade, KPH, or 12
th
 rib fat 
thickness. Increased HCW and dressing percentage have been observed consistently with ZH 
supplementation in feedlot cattle (Vasconcelos et al., 2008; Elam et al., 2009; and Hilton et al., 
2009). Montgomery et al. (2009a) compared response to ZH in steers and heifers for periods of 
20 or 40 d, and observed decreases in marbling scores and quality grades (P = 0.002) for steers, 
and a decrease in quality grade (P < 0.05) for heifers; however, ZH did not affect 12
th
 rib fat 
thickness or KPH (P > 0.10) in carcasses from either sex. Additionally, Vasconcelos et al. (2008) 
observed larger LM area, lower yield grade, and lower marbling scores (P< 0.01) when 
comparing ZH supplemented for final 0, 20, 30, or 40 d for finishing periods consisting of 136, 
157, 177, or 198 d on feed compared to control animals. Conversely, Placencia et al. (2008) fed 
steers 0 or 6 mg/kg ZH (as fed basis) to steers and reported no effect of ZH on LM area, quality 
grade, or marbling score (P > 0.20) when compared to un-treated steers. Our results suggest 
increases in HCW are due to increased skeletal muscle mass, which is consistent with 
observations of increased LM area in treated steers. The lack of effect on carcass measurements 
associated with fat deposition may be a consequence of limited statistical power with the small 
population size of cattle we utilized for this study compared to previously cited studies.  
In conclusion, feeding ZH decreased PUN concentrations indicating nitrogen may be 
utilized more efficiently to accommodate increased carcass weight and LM area in supplemented 
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steers. Blood constituents, and carcass measurements related to lipolysis were mostly unchanged, 
which is suggestive of ZH having a smaller effect on adipose tissue lipolysis compared to 
skeletal muscle accretion. 
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Table 2.1: Diet Composition, DM basis 
Ingredients %, DM basis 
Wet distiller’s grain with solubles 30.00 
Steam flaked corn 58.32 
Wheat straw 7.00 
Monensin/tylosin premix
1
 2.16 
Vitamin/mineral premix
2 
0.41 
    Limestone 1.81 
    Salt 0.30 
Analyzed composition, %   
    CP 15.2 
    Ca 0.7 
    P 0.4 
    K 0.8 
    NDF 18.6 
1
Formulated to provide 300 mg/d monensin and 90 mg/d tylosin (Elanco Animal Health, 
Greenfield, IN) in a ground corn carrier.  
2
Formulated to provide; 2,200 IU/kg vitamin A; 22 IU/kg vitamin E; 10 mg/kg added Cu; 60 
mg/kg added Zn; 60 mg/kg added Mn; 0.5 mg/kg added I; 0.25 mg/kg added Se, and 0.15 
mg/kg Co. Zilpaterol-HCl (Merck Animal Health, Millsboro, DE), was fed 23 d at 8.33 mg/kg 
of diet DM followed by a 3-d withdrawal prior to harvest. 
56 
 
Table 2.2: Feedlot performance of steers fed 0 or 8.33 mg/kg diet DM zilpaterol 
hydrochloride (ZH)
1 
Item        Control ZH SEM P-Value 
No. steers 8 9 - - 
Initial BW, kg
a 
614 615 10.48 0.60 
Final BW, kg
a 
658 660 13.76 0.72 
DMI, kg/d 11.87 10.95 0.46 0.03 
ADG, kg 1.67 1.73 0.54 0.83 
G:F 0.1399 0.1535 0.0191 0.56 
1
ZH (Merck Animal Health, Millsboro, DE) was fed for 23 d followed by a 3-d withdrawal prior 
to harvest. 
a
Initial and final BW are calculated as gross BW × 0.96.
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 1 
Table 2.3: Concentrations of blood metabolites at weekly intervals for steers fed 0 or 8.33 mg/kg diet DM zilpaterol 2 
hydrochloride (ZH)
1 
3 
 D 0  D 7  D 14  D 21  
Item, mM Control ZH Control ZH Control ZH Control ZH SEM
2 
Whole blood glucose
‡
  
 
3.32
ab 
3.39
b 
3.33
ab 
3.01
a 
3.48
ab 
3.12
a 
3.48
ab 
3.09
a 
0.24 
Whole blood lactate
† 
2.83 2.80 2.45 1.43 2.37 1.37 2.16 1.54 0.48 
 
Plasma glucose 5.17 5.21 5.33 4.77 5.23 4.96 5.38 5.10 0.36 
 
Plasma lactate
† 
4.28 4.29 4.00 2.31 3.71 2.19 3.20 2.62 0.79 
 
NEFA 126 175 172 192 164 184 140 174 36 
 
BHB
3 
0.06 0.07 0.09 0.08 0.07 0.08 0.09 0.08 0.02 
1
ZH (Merck Animal Health, Millsboro, DE) was fed for 23 d followed by a 3-d withdrawal before harvest.  4 
‡
ZH × d interaction, P < 0.10. 5 
ab
Within a row, means without a common superscript letter are different; P < 0.10. 6 
†
Effect of d, P < 0.10. 7 
2
SEM listed is greater SEM of two treatments.
  
8 
3
Beta hydroxybutyrate, BHB. 9 
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Figure 2.1: Concentration of plasma urea nitrogen at weekly intervals for steers fed 0 (■) 10 
or 8.33 (♦) mg/kg diet DM zilpaterol hydrochloride. 11 
ZH × sampling d interaction, P = 0.06; effect of d, P = 0.69; effect of ZH, P < 0.05; SEM = 0.24   12 
a, b
 means within d with different letters are different, P = 0.06.  13 
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Table 2.4: Plasma concentrations of long-chain fatty acids at weekly intervals for steers fed 0 or 8.33 mg/kg diet DM zilpaterol 15 
hydrochloride (ZH)
1 
16 
 D 0  D 7  D 14  D 21  
Item (ug/g)
2 
Control ZH  Control ZH  Control ZH  Control ZH SEM 
C14:0 16.7 20.0  16.4 16.0  18.9 18.9  17.6 18.2 1.91 
C14:1 12.7 13.6  11.5 10.8  10.6 13.6  12.6 14.0 1.16 
C15:0
† 
21.4   20  20.9 23  24.9 23.9  27.1 27.9 1.64 
C15:1     6.3 7.7  6.4 7  5.6 7.7  7.4 6.8 0.99 
C16:0
† 
206 199  204 219  205 237  210 242 13.6 
C16:1
† 
17 20  12.4 15  14.3 13.6  12.1 11.4 1.80 
C17:0 24.2 26.2  25.4 26.8  28.8 30.7  25.6 28.7 2.46 
C17:1 6.6 9.4  5.8 6.1  6.5 7.2  6.5 6.1 1.18 
C18:0
† 
297 302  345 342  343 391  373 405 27.3 
C18:1n9t
†,‡ 
41.7
abc 
36.5
a 
 60.3
d 
52.3
cd 
 35.9
ab 
50.2
bcd 
 40.1
ab 
62.6
d 
6.88 
C18:1n11
† 
0 1.2  1.7 0  1.6 0.9  4.7 3 1.44 
C18:1n9c
† 
121 121  108 108  108 119  111 125 8.37 
C18:1n7
‡ 
14.5
abc 
12.4
a 
 14.9
abc 
13.7
ab 
 12.7
ab 
15.1
bc 
 12.7
ab 
16.1
c 
1.12 
C18:2n6t
 
4.3 1.9  5.5 2.6  2 3.3  2.7 2.8 1.20 
C18:2n6c
† 
1,201 1,142  1,224 1,286  1,246 1,380  1,270 1,478 104 
C18:3n6 18.1 19.7  21 15.8  17.6 18.1  13.1 18.1 2.70 
C18:3n3
† 
34.8 31.9  27 28.7  25.8 23.6  25.1 26.4 3.17 
C20:3n6 33.6 41.5  26.7 35.5  31.4 30.3  28.8 38.3 5.27 
C20:4n6 2.6 2.3  2.9 4.4  3.7 2.7  2.1 4.3 1.18 
C20:5n3 4 2.3  4.4 2.1  3.3 2.9  3.6 5.3 1.38 
C22:5n3
‡ 
31.6
ab 
28.5
ab 
 35.7
b 
25.7
a 
 22
a 
34.3
ab 
 26.5
ab 
39.8
b 
6.76 
C22:6n3 33.6 25.4  41.1 27.6  27.7 39.6  30.5 42.7 10.59 
Total LCFA
†                                          
2,149 2,082  2,221 2,268  2,194 2,463  2,262 2,623 164 
1
ZH (Merck Animal Health, Millsboro, DE) was fed for 23 d followed by a 3-d withdrawal prior to harvest. 17 
60 
 
2
Nomenclature of fatty acids is as follows: example, C14:0 = a fatty acid with 14 carbon atoms and no double bonds; C18:1n9c = a 18 
fatty acid with 18 carbon atoms and 1 double bond located at the 9
th
 carbon in the cis configuration; “t” indicates the double bond is 19 
in the trans configuration.  20 
†
Effect of d, P < 0.10. 21 
‡
Treatment × d interaction, P < 0.10. 22 
abcd
Within a row, means without a common superscript letter are different, P < 0.10.23 
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Table 2.5: Concentrations of long-chain fatty acids from steers fed 0 or 8.33 mg/kg diet 24 
DM zilpaterol hydrochloride (ZH)
1
 within adipose tissue collected from subcutaneous fat 25 
covering lumbar vertebrae.
 
26 
Item, % of sample
2 
Control ZH SEM P-Value 
C14:0 2.514 2.557 0.146 0.84 
C14:1 0.358 0.341 0.015 0.46 
C15:0 0.012 0.011 0.001 0.59 
C15:1 0.013 0.020 0.003 0.11 
C16:0 18.468 18.114 0.502 0.54 
C16:1 3.052 3.140 0.262 0.76 
C17:0 1.122 1.028 0.052 0.18 
C17:1 0.593 0.540 0.023 0.14 
C18:0 11.44 11.25 0.742 0.86 
C18:1n9t 2.731 2.834 0.210 0.73 
C18:1n11 0.432 0.477 0.035 0.38 
C18:1n9c 29.69 28.64 0.639 0.15 
C18:1n7 1.284 1.264 0.051 0.78 
C18:2n6t 0.159 0.176 0.010 0.21 
C18:2n6c 1.547 1.580 0.121 0.85 
c9, t11 CLA 0.053 0.063 0.006 0.17 
t10, c12 CLA 0.011 0.015 0.005 0.60 
c9, c11 CLA 0.002 0.006 0.002 0.22 
t9, t11 CLA 0.203 0.235 0.021 0.20 
C18:3n6 0.043 0.042 0.007 0.92 
C18:3n3 0.132 0.139 0.012 0.66 
C20:0 0.064 0.081 0.010 0.26 
C20:1 0.180 0.189 0.019 0.76 
C20:2 0.0799 0.0804 0.007 0.96 
C20:3n6 0.046 0.052 0.007 0.52 
C20:4n6 0.0096 0.0104 0.002 0.74 
C20:5n3 0.007 0.004 0.002 0.37 
C21:0
 
0.101 0.219 0.021 0.01 
C22:0 0.018 0.014 0.005 0.45 
C22:5n3 0.0049 0.0045 0.002 0.87 
C22:6n3 0.006 0.009 0.002 0.30 
C24:0 0.008 0.005 0.002 0.22 
C24:1 0.003 0.004 0.001 0.56 
Total fatty acids 74.9 73.8 1.84 0.66 
1
ZH (Merck Animal Health, Millsboro, DE) was fed for 23 d followed by a 3-d withdrawal 27 
prior to harvest. 28 
 
29 
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2
Nomenclature of fatty acids are as follows: example, C14:0 = a fatty acid with 14 carbon atoms 30 
and no double bonds; C18:1n9c = a fatty acid with 18 carbon atoms and 1 double bond located 31 
at the 9
th
 carbon and is in the cis configuration; “t” indicates the double bond is in the trans 32 
configuration.  c9, t11 CLA = conjugated linoleic acid with double bonds located on the 9
th
 (cis 33 
configuration) and the 11
th
 (trans configuration) carbon atoms.  34 
35 
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 36 
Table 2.6: Carcass characteristics for steers fed 0 or 8.33 mg/kg diet DM zilpaterol 37 
hydrochloride (ZH)
1
 38 
Item Control ZH SEM P-Value 
HCW, kg 415 429 8.98 0.02 
Dressed yield, % 63.1 65.0 0.68 0.08 
Liver abscesses, % 0 0 - - 
LM area, cm
2 
          88.64 99.22 3.55 0.07 
12th rib fat, cm
 
0.92 0.84 0.11 0.63 
KPH, % 2.06 2.06 0.169 0.98 
USDA yield grade 2.6 2.0 0.26 0.12 
Marbling score
a 
408 378 28.5 0.47 
USDA Choice, % 26.1 44.4 17.6 0.44 
USDA Select, % 73.9 55.6 17.6 0.44 
1
ZH (Merck Animal Health, Millsboro, DE) was fed for 23 d followed by a 3-d withdrawal 39 
prior to harvest. 40 
a 
Marbling scores were determined by a USDA grader; Slight = 300 to 399;
 
41 
Small = 400 to 499; Modest = 500 to 599. 42 
43 
  
64 
 
Chapter 3 - Manipulation of Dietary Calcium Concentration to 44 
Potentiate Changes in Tenderness of Beef from Heifers 45 
Supplemented with Zilpaterol Hydrochloride  46 
C. L. Van Bibber-Krueger, K. A. Miller, and J. S. Drouillard
1 
47 
Department of Animal Sciences and Industry, Kansas State University, Manhattan, KS 66506 48 
1
Corresponding author: jdrouill@ksu.edu49 
  
65 
 
 50 
 Abstract 51 
Dietary calcium concentrations were manipulated during supplementation of zilpaterol 52 
hydrochloride (ZH) to evaluate impact on feedlot performance, carcass characteristics, and beef 53 
tenderness using 96 heifers (BW 392 kg ± 3.2). We hypothesized that temporary depletion 54 
followed by repletion of dietary calcium prior to harvest would increase intracellular calcium 55 
concentrations, thus stimulating postmortem activity of calcium-dependent proteases to effect 56 
changes in tenderness. Heifers were stratified by initial BW and randomly assigned, within 57 
strata (block), to treatments consisting of a finishing diet in which calcium was added in the 58 
form of limestone (+Ca) or removed (-Ca) during ZH supplementation. Cattle were fed a 59 
common diet prior to ZH supplementation, and 28 d prior to slaughter ZH was added to the diet 60 
with and without supplemental calcium. Calcium content of the diets during ZH 61 
supplementation was 0.74% or 0.19% (diet DM) for +Ca and -Ca, respectively. Zilpaterol 62 
hydrochloride was fed for 25 d then removed from the diet 3 d prior to harvest. The final 3 d 63 
before harvest all cattle were fed calcium at 0.74% of diet DM. Heifers were housed in concrete 64 
surfaced pens with 8 animals/pen (6 pens/treatment). At the end of the finishing phase animals 65 
were weighed and transported to an abattoir in Holcomb, Kansas. Severity of liver abscesses 66 
and HCW were collected the day of harvest, and after 48-h of refrigeration USDA yield and 67 
quality grades, KPH, LM area, and 12
th
 rib subcutaneous fat thickness were determined. 68 
Additionally, boneless loin sections were collected for Warner-Bratzler shear force 69 
determination. Removal of calcium did not affect Warner-Bratzler shear force values (P = 0.64). 70 
In addition, ADG, DMI, final BW and feed efficiency were unaffected by treatment (P > 0.05). 71 
Carcass measurements also were unaffected by the temporary decrease in dietary calcium (P > 72 
0.05). In conclusion, temporary depletion of dietary calcium did not alter beef tenderness, live 73 
animal performance, or carcass measurements.  74 
Key words; beef tenderness, calcium, ruminant, zilpaterol hydrochloride  75 
 Introduction 76 
The addition of a zilpaterol hydrochloride (ZH) to diets of finishing cattle has 77 
consistently demonstrated a decrease in meat tenderness (Leheska et al., 2009; Shook et al., 78 
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2009; Garmyn et al., 2010). Tenderness is one of the most important characteristics of meat for 79 
consumer acceptance (Koohmaraie, 1992). The calpain proteolytic system consists of calcium 80 
dependent proteolytic enzymes m-calpain and µ-calpain, and the inhibitor calpastatin (Goll et 81 
al., 1998), and is mostly responsible for post-mortem tenderization of meat. There is evidence to 82 
suggest that increasing calcium ion concentrations in skeletal muscle cells results in weakening 83 
of myofibrillar structures, which aids in post-mortem tenderization (Koohmaraie, 1992). To 84 
potentiate the decrease in tenderness, calcium chloride has been infused in meat post-mortem 85 
and observed to increase tenderness (Morgan et al., 1991). 86 
Removal of calcium from diets of dairy cows prior to parturition has been used to 87 
activate homeostatic mechanisms required to prevent milk fever (Thilsing-Hansen et al., 2002). 88 
Decreased dietary calcium stimulates parathyroid hormone (PTH), which is necessary for 89 
calcium reabsorption from glomerular filtrate and resorption of calcium stored in bone (Horst et 90 
al., 1997). Activation of homeostatic mechanisms during periods of temporary depletion of 91 
calcium prior to parturition in dairy cattle resulted in decreased incidences of milk fever 92 
(Hillman, 1967).We hypothesized that temporary depletion of dietary calcium could be 93 
exploited to increase bone resorption, and when followed by repletion of normal dietary calcium 94 
concentration, elevate intracellular calcium concentration temporarily, thus stimulating 95 
postmortem activity of calcium-dependent proteases. The objective of our study was to 96 
temporarily deplete dietary calcium during ZH administration in an effort to overcome adverse 97 
effects of ZH on meat tenderness. 98 
  Materials and Methods 99 
 Animals and sampling 100 
Protocols and procedures followed in this study were approved by the Kansas State 101 
University Institutional Animal Care and Use Committee. The study was conducted at the 102 
Kansas State University Beef Cattle Research Center in Manhattan, KS. 103 
Ninety six crossbred heifers (initial BW = 392 kg ± 3.2) were stratified by BW and 104 
randomly allocated, within strata, to two treatment groups for a 116-d finishing trial. Heifers 105 
were identified using ear tags that displayed a number unique to each study animal. Cattle were 106 
allotted to feeding pens equipped with concrete floors, fence line feed bunks, and automatic 107 
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water fountains with 8 animals/pen (6 pens/treatment). Heifers were fed once daily to allow ad 108 
libitum intake of feed. A pre-ZH diet (0.78% calcium, DM basis) was fed until the final 28 d of 109 
finishing, at which time ZH was included in the diet. Zilpaterol hydrochloride was fed at a rate 110 
of 8.33 mg/kg of diet DM for a period of 25 d, and then withdrawn from diets 3 d before 111 
harvest. Treatments consisted of diets containing supplemental calcium (+Ca; 0.74% of DM) in 112 
the form of limestone, or a diet from which limestone had been removed (-Ca; 0.19% of DM) 113 
during ZH supplementation. Diets are presented in table 3.1. The final 3 d before harvest cattle 114 
were fed a common diet containing 0.74% calcium (DM basis). 115 
Feed deliveries to each pen were monitored daily, and unconsumed feed was removed 116 
from the bunk, weighed, and dried at weekly intervals or as needed to determine actual feed 117 
DMI. Feedstuffs were sampled weekly and analyzed for DM, starch, NDF, CP, S, and ether 118 
extract. Portions of ground samples of feedstuffs were dried in a forced air oven at 105°C 119 
overnight to determine DM (Undersander et al., 1993). Starch contents of feedstuffs were 120 
determined according to Herrera-Saldana and Huber (1989) with a Technicon Autoanalyzer III 121 
(SEAL Analytical, Mequon, WI). Determination of NDF was conducted using an ANKOM 122 
fiber analyzer (ANKOM Technology Corp., Fairport, NY) according to Van Soest et al. (1991).  123 
Heat-stable α-amylase (ANKOM Technology Corp) was added to remove residual starch from 124 
feedstuff samples. Determination of CP was accomplished by measuring N content with a 125 
LECO FP–2000 nitrogen analyzer (LECO Corp., St Joseph, MI) following AOAC (1995) 126 
official method 990.03. Ether extract was performed according to AOAC (1995) official method 127 
920.39.  128 
Average daily gains were computed by subtracting pre-ZH shrunk BW from final shrunk 129 
BW (gross BW * 0.96), and dividing by days on feed (DOF). Gain efficiencies were computed 130 
by dividing ADG by DMI. Body weights were measured for each pen at 28-d intervals to 131 
determine proper time for ZH supplementation. Body weights were measured prior to ZH 132 
supplementation and shrunk final BW (gross BW * 0.96) were determined immediately before 133 
cattle were shipped on the d of harvest. Heifers were harvested when they achieved an estimated 134 
12
th
-rib subcutaneous fat thickness of 1cm. Heifers were then loaded onto a truck and 135 
transported 451 km to a commercial abattoir in Holcomb, Kansas. Incidence and severity of 136 
liver abscesses and HCW were recorded the day of harvest. Liver abscesses were scored 137 
according to the Elanco scoring system (Liver Abscess Technical Information AI 6288, Elanco 138 
  
68 
 
Animal Health, Greenfield, IN): 0 = no abscesses; A
-
 = 1 or 2 small abscesses or abscess scars; 139 
A
0
 = 2 to 4 small well-organized abscesses; and A
+
 = 1 or more large or active abscesses with or 140 
without adhesions. Yield Grade, quality grade, marbling score, 12
th
-rib subcutaneous fat 141 
thickness, LM area, percent KPH, and incidence and severity of dark cutting beef were 142 
determine after 48 h of refrigeration. Finally, a loin section weighing approximately 800 g was 143 
collected from one side of each carcass, placed on ice, and transported to Kansas State 144 
University, Manhattan, KS.   145 
 Warner-Bratzler shear force and moisture determinations 146 
Loin sections were refrigerated overnight at 1ºC after arrival at Kansas State University. 147 
The following d samples were weighed and placed into 15.2 × 30.4 cm vacuum bags (3 mil 148 
standard barrier, Prime Source Vacuum Pouches; Bunzl Processor Division, Koch Supplies, 149 
Kansas City, MO) that had an oxygen transmission rate of 3.5 g · 645 cm-2 · 24 h-1 at 21ºC, and 150 
water vapor transmission rate of 0.6 mL · 645 cm-2 · 24 h-1 at 38ºC. The bags were vacuum 151 
sealed and aged for 14 d post-mortem at a temperature of 1ºC. Following aging, loin sections 152 
were removed from the bags, patted dry using paper towels, and weighed. Percent purge loss 153 
was calculated as: [(pre-aged weight – aged weight)/pre-aged weight] × 100. Prior to cooking, a 154 
single 2.54-cm steak was removed from the 13th rib face for Warner-Bratzler shear force 155 
determination. 156 
Steaks for Warner-Bratzler Shear (WBSF) were weighed and then cooked in a Blodgett 157 
oven (model number DFG-102, The G.S. Blodgett Company, Inc. Burlington, VT) at a 158 
temperature of 163°C. Thermocouple wires (thirty gauge copper and constantan; Omega 159 
Engineering, Stamford, CT) were inserted into steaks and internal temperatures were monitored 160 
using a Doric Minitrend 205 (VAS Engineering, San Francisco, CA). Steaks were turned when 161 
internal temperature reached 40°C and removed from the oven when an internal temperature of 162 
70°C was achieved. Steaks were allowed to temper for handling and then reweighed to calculate 163 
percent moisture loss during cooking as: [(raw weight – cooked weight)/raw weight] × 100. 164 
Steaks were then covered with plastic wrap and refrigerated at approximately 3 to 4°C for 24 h. 165 
Following 24-h of refrigeration, eight 1.25-cm diameter cores were taken from each steak 166 
parallel to the muscle fiber orientation and sheared perpendicular to the fiber orientation on an 167 
INSTRON Model 5569 Universal Testing Machine (Canton, MA) equipped with a Warner-168 
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Bratzler shear head. A 100-kg compression load cell was used with a crosshead speed of 250 169 
mm/min. Shear force was determined for each core, and the mean of 8 core samples was 170 
calculated. 171 
 Statistical Analyses 172 
The experiment was designed as a randomized complete block experiment with pen as 173 
the experimental unit. The MIXED procedure of SAS version 9.2 (SAS Inst. Inc., Cary, NC) 174 
was used to analyze performance, carcass, and shear force data. Incidence of liver abscess and 175 
USDA quality grade were analyzed using the GLIMMIX procedure of SAS. Models included 176 
calcium as the fixed effect and block as the random effect. For performance data, pre-treatment 177 
BW, ADG, DMI and G:F were utilized as covariates for final BW, ADG, DMI, and G:F. The 178 
LSMEANS statement was used for means and standard error calculations, and the PDIFF option 179 
used for separation of means. Separation of means were determined to be significant at α level ≤ 180 
0.05. 181 
 Results and Discussion 182 
One animal from the -Ca treatment was removed from the study due to a physical injury.  183 
Final BW, ADG, DMI and feed efficiency (table 3.2) were not different for heifers fed   184 
-Ca and +Ca (P > 0.05). In agreement with our results, Jackson and Hemken (1994) performed 185 
a study to evaluate effects of calcium and cation-anion balance in Holstein calves. Calcium 186 
concentrations were 0.42 or 0.52% of diet DM, yielding dietary anion-cation balances of -18 or 187 
+13 for the low and high calcium concentrations, respectively. The authors observed no 188 
differences in ADG or DMI (P > 0.05) between the two calcium concentrations, which 189 
indicated 0.42% calcium concentration was adequate. Varner and Woods (1972) conducted 2 190 
trials that used 24 steers/trial. Each trial had a length of 137 d. Steers were fed diets that 191 
contained 0.20, 0.31, 0.42, or 0.53% (diet DM) calcium. The authors observed an increase in 192 
ADG, DMI, and feed efficiency when steers were supplemented with 0.31 and 0.42% calcium 193 
(P < 0.05), but found no further improvement with 0.53% calcium supplementation. Cattle in 194 
the study performed by Varner and Woods (1972) were fed calcium deficient diets for a longer 195 
period of time compared to heifers in our experiment possibly explaining the contrasting results. 196 
The 25-d depletion of calcium in the current experiment may not have been sufficiently long to 197 
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observe differences in animal performance. Cattle that are beyond the primary stage of bone 198 
growth can be fed calcium deficient diets for an extended period of time without developing 199 
signs of calcium deficiency if previous calcium intake was adequate (NRC, 1996). Our results 200 
indicate temporary depletion of calcium did not affect performance of feedlot heifers.  201 
Tenderness is one of the most important characteristics of meat for consumer acceptance 202 
(Koohmaraie,1992). Removing supplemental calcium from the diet had no effect on WBSF 203 
values (P > 0.05; presented in table 3.3). Additionally, percent moisture lost as purge and during 204 
cooking was not affected by calcium depletion (P > 0.05). Hilton et al. (2009) conducted a 205 
study in which ZH was administered with and without monensin and tylosin. The authors 206 
demonstrated no difference in percent weight lost during cooking (P > 0.10) with and without 207 
ZH. Duckett et al. (2000) administered a calcium gel to steers 3 to 6 h prior to slaughter, and 208 
observed steaks from steers treated with oral calcium gel had lower WBSF values at early 209 
postmortem ages (P < 0.05), but not at later postmortem ages (P > 0.05) compared to steers that 210 
did not receive oral calcium gel. In agreement with our study, Spears et al. (2003) observed that 211 
adding calcium propionate at 4% (as fed) to diets of steers 7 d prior to slaughter did not affect 212 
WBSF values (P > 0.05). Lack of effect on WBSF in the current study may suggest we can’t 213 
substantially alter intracellular calcium concentration by this method, or 3-d replenishment was 214 
enough time for the heifers to reach plasma calcium homeostasis. Pickard (1975) demonstrated 215 
dairy cows plasma calcium levels returned to normal 2 days after calving in all cows tested. 216 
Another explanation for the lack of an effect on tenderness may be there was not a sufficient 217 
amount of calcium in the diet during replenishment to increase intracellular calcium. 218 
Additionally, Thilsing-Hansen et al. (2002) indicated dairy diets need to provide fewer than 20 219 
g of calcium daily to release PTH. In our study, heifers fed the -Ca diet consumed 220 
approximately 26 g/d, which may not have been sufficiently low to activate homeostatic 221 
mechanisms. 222 
Carcass characteristics in this study were unaffected by supplemental calcium (P > 0.05; 223 
table 3.4). Varner and Woods (1972) observed no differences in carcass characteristics when 224 
steers were fed diets containing 0.20, 0.31, 0.42, or 0.53% (diet DM) calcium. Additionally, 225 
Duckett et al. (2000) and Spears et al. (2003) observed no differences in carcass traits when 226 
steers were administered calcium gel 3 to 6 h before slaughter or calcium propionate 7 d before 227 
slaughter, respectively.  The lack of differences in carcass measurements may be attributed to 228 
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adequate storage of calcium in bone of research animals to negate calcium deficiencies 229 
commonly found in young animals that have received inadequate dietary calcium (NRC, 1996).  230 
In conclusion, temporarily depleting calcium from finishing diets during ZH 231 
supplementation did no impact WBSF values, carcass traits, or live performance indicating we 232 
did alter tenderness by temporary depletion of dietary calcium. 233 
234 
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 302 
Table 3.1: Diet Composition, DM basis 303 
Ingredients, % Pre-ZH +Ca -Ca 
Dry-rolled corn 35.92 30.97 32.40 
Wet corn gluten feed 29.96 35.00 35.00 
Corn silage 9.99 10.00 10.00 
Soybean hull pellets 19.97 20.00 20.00 
Feed additive premix
1 
2.16 2.16 2.16 
Vitamin/trace mineral premix
2 
0.12 0.12 0.12 
Limestone 1.56 1.45                   - 
Salt 0.32 0.30 0.32 
Analyzed composition, % 
    CP 14.07 14.80 14.94 
    Ca 0.78 0.74 0.19 
    P 0.48 0.51 0.51 
    K 0.85 0.88 0.89 
    NDF 29.12 30.37 30.50 
1
Formulated to provide 300 mg/d monensin and 90 mg/d tylosin (Elanco Animal Health, 304 
Greenfield, IN); and 0.5 mg MGA (Elanco Animal Health, Greenfield, IN) in a ground corn 305 
carrier; Zilpaterol-HCl (Merck Animal Health, Millsboro, DE) was fed for 25 d at 8.33 mg/kg 306 
of diet DM followed by a 3-d withdrawal prior to harvest. 307 
2
Formulated to provide 2,200 IU/kg vitamin A; 22 IU/kg vitamin E; 10 mg/kg added Cu; 60 308 
mg/kg added Zn; 60 mg/kg added Mn; 0.5 mg/kg added I; 0.25 mg/kg added Se; and 0.15 309 
mg/kg added Co.  310 
311 
  
75 
 
 312 
Table 3.2: Feedlot performance for heifers fed with and without supplemental calcium 313 
during zilpaterol hydrochloride (ZH) supplementation
1 
314 
Item +Ca -Ca SEM P-value 
Pre ZH BW, kg
a 
547 548 5.91 0.85 
Final BW, kg
a
 580 583 2.09 0.29 
ADG, kg 0.93 1.01 0.05 0.37 
DMI, kg 11.93 11.03 0.31 0.11 
G:F 0.0792 0.0904 0.006 0.42 
1
ZH (Merck Animal Health, Millsboro, DE) was supplemented at a rate of 8.33 mg/kg diet DM 315 
for 25 d followed by a 3-d withdrawal prior to harvest. 316 
a
Pre ZH and final BW calculated as  gross BW × 0.96. 317 
 318 
319 
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 320 
Table 3.3: Carcass characteristics for heifers fed with and without supplemental calcium 321 
during zilpaterol hydrochloride (ZH) supplementation
1
 322 
Item +Ca -Ca SEM P-value 
HCW, kg  372 374 3.76 0.57 
Dressed yield, % 64.17 64.10 0.36 0.85 
Liver abscesses, % 2.08 8.33 4.27 0.20 
USDA yield grade 2.57 2.42 0.12 0.23 
LM area, cm
2
 94.0 96.0 1.59 0.27 
12
th
 rib fat thickness, cm 1.40 1.50 0.14 0.55 
KPH, % 3.14 3.13 0.10 0.89 
Marbling score
a 
496 501 14.63 0.73 
USDA Prime, % 2.39 2.08 3.16 0.93 
USDA Choice, % 82.74 87.50 6.37 0.49 
USDA Select, % 10.71 6.25 5.77 0.47 
Low grade, % 2.08 4.17 3.29 0.36 
No roll, % 2.08 - 1.47 0.36 
1
ZH (Merck Animal Health, Millsboro, DE) was supplemented at a rate of 8.33 mg/kg diet DM 323 
for 25 d followed by a 3-d withdrawal prior to harvest. 324 
a
Marbling scores were determined by a USDA grader; Slight = 300 to 399; 325 
Small = 400 to 499; Modest = 500 to 599. 326 
327 
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 328 
Table 3.4: Meat tenderness and cooking attributes for heifers fed with and without 329 
supplemental calcium during zilpaterol hydrochloride (ZH) supplementation
1
 330 
Item +Ca -Ca SEM P-value 
Purge loss, %
a 
1.63 1.96 0.002 0.18 
Moisture lost during cooking, %
b 
19.5 19.3 0.01 0.83 
Shear force, kg 4.64 4.58 0.12 0.64 
1
ZH (Merck Animal Health, Millsboro, DE) was supplemented at a rate of 8.33 mg/kg diet DM 331 
for 25 d followed by a 3-d withdrawal prior to harvest. Loin sections were aged 14 d post-332 
mortem. 333 
a
Purge loss refers to the amount of moisture lost during the aging process. 334 
b
Moisture lost during the cooking process when LM steaks were cooked to an internal 335 
temperature of 70ºC. 336 
337 
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 345 
 Abstract 346 
Effects of menthol on blood metabolites were evaluated using Holstein steers (n = 52, 347 
BW 573 ± 9.92 kg) that were blocked by BW and assigned within block to treatment. 348 
Treatments consisted of 0%, 0.003%, 0.03%, or 0.3% crystalline menthol (DM basis) added to 349 
the diet. Animals were housed in individual, partially covered pens equipped with feed bunks 350 
and automatic water fountains. On d 1 of the experiment, blood samples were obtained via 351 
jugular venipuncture at 0, 6, 12, 18, and 24 h after feeding. Treatment administration 352 
commenced on d 2, and blood samples were again drawn at 0, 6, 12, 18, and 24 h after feeding. 353 
This blood-sampling schedule was repeated on d 9, 16, 23, and 30. Plasma was analyzed for 354 
plasma urea nitrogen (PUN), glucose, and lactate concentrations. Serum was used to analyze 355 
IGF-1 concentration. Additionally, BW was measured on d 1, h 0 and again at each time point 356 
on d 9, 16, 23, and 30. In addition to the live animal phase of the study, in vitro fermentations 357 
were performed using ruminal fluid cultures. Measurements included VFA concentrations, and 358 
fermentative gas production for cultures containing crystalline menthol at 0%, 0.003%, 0.03%, 359 
or 0.3% of substrate DM. Addition of menthol to the diet of steers resulted in a menthol × time 360 
within d interaction (P < 0.01) for concentration of IGF-1 and BW. Cattle fed 0.003% menthol 361 
had greater serum concentrations of IGF-1 at the start of the study compared to other treatments 362 
and maintained a greater concentration until d 23 when compared to 0.03% and 0.3% menthol 363 
treated steers. A menthol × d interaction (P < 0.05) was observed for daily feed deliveries: cattle 364 
fed 0.3% menthol consumed less feed d 1 thru 13. Glucose, lactate, and PUN concentrations 365 
were unaffected by addition of menthol to the diet (P > 0.05). Furthermore, in vitro 366 
concentrations of VFA were unaffected by menthol (P > 0.05); however, menthol, regardless of 367 
concentration, decreased (P < 0.01) fermentative gas production in vitro. In summary, increased 368 
concentrations of menthol had lower IGF-1 concentrations; however, other blood constituents 369 
related to growth were unaffected by addition of menthol to the diet. Menthol decreased the 370 
amount of gas produced by ruminal microorganisms, but had no effect on concentrations of 371 
VFA produced. 372 
Key words; IGF-1, menthol, plasma urea nitrogen, ruminant 373 
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 Introduction 374 
Menthol is a naturally occurring compound classified as an essential oil that gives plants 375 
of the Mentha species their minty characteristic aroma and flavor. Menthol is utilized as a 376 
cooling compound in products ranging from common cold medications to pesticides, and has 377 
been found to have a wide range of biological activities on different systems within the body. 378 
Menthol affects smooth muscle in the lungs and heart by interfering with movement of calcium 379 
across the cell membrane (Eccles, 1994). Santos et al. (2011) discussed the ability of menthol to 380 
dilate human forearm cutaneous vessels and induce vasodilation in rat arteries. Menthol also 381 
affects TRP-independent channels, which can affect cellular calcium transport (Kim et al., 2008, 382 
Manhieu et al., 2007, Swandulla et al., 1986). More recently, studies with livestock have 383 
utilized menthol and other essential oils as potential alternatives to feed antibiotics and growth 384 
promotants (Soltan, 2010).  385 
Menthol has been observed to directly affect κ-opioid receptors causing antinociception 386 
in mice (Galeotti et al., 2002). Kappa opioid receptors are located in the central nervous system 387 
with a high density found in the hypothalamus (Meng et al., 1993). In a preliminary experiment, 388 
improvements in growth and increases in circulating concentrations of IGF-1 were observed 389 
with short-term oral administration of crystalline menthol (Parsons et al., Kansas State 390 
University, Manhattan, KS, personal communication). It was hypothesized menthol may be 391 
capable of binding to κ-opioid receptors in the hypothalamus stimulating neuropeptides 392 
involved in production and release of GH, thus increasing growth. Our objective was to evaluate 393 
changes in blood metabolites when menthol was incorporated into diets of steers. We 394 
hypothesized that menthol would increase concentrations of IGF-1 when fed to finishing cattle. 395 
 Materials and Methods 396 
 Animals and Sampling 397 
Protocols and procedures followed in this study were approved by the Kansas State 398 
University Institutional Animal Care and Use Committee.  399 
 The study was conducted using 52 Holstein steers (initial BW = 573 ± 9.92 kg) 400 
obtained from a single source. Steers were weighed, stratified into weight blocks, and assigned 401 
randomly within block to 4 treatment groups. Steers were housed in individual feeding stalls 402 
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equipped with fence line mangers and automatic water fountains. The pens were partially 403 
covered and grouped into 3 barns with 20 animals in 2 barns and 12 animals in the third barn. 404 
Diets consisted of 93% concentrate and 7% roughage (table 4.1). Treatments consisted of 405 
menthol added at 0%, 0.003%, 0.03%, or 0.3% of diet DM. Barn A was fed at approximately 406 
1500 h, Barn B was fed at approximately 1600 h, and Barn C was fed at approximately 1700 h 407 
daily. Menthol was provided by Ind-Swift Laboratories Limited (Dover, DE) 408 
On d 1 of the experiment, blood samples were obtained via jugular venipuncture at 0, 6, 409 
12, 18, and 24 h after feeding. Treatment administration commenced on d 2, and blood samples 410 
were again drawn at 0, 6, 12, 18, and 24 h after feeding. This blood sampling schedule was 411 
repeated on d 9, 16, 23, and 30. Body weights were measured on d 1, h 0 and then at 0, 6, 12, 412 
18, and 24 h post-feeding on d 9, 16, 23, and 30. Blood samples were collected using two 6-mL 413 
blood tubes containing EDTA (Vacutainer, Becton Dickinson, Franklin Lakes, NJ) as 414 
anticoagulant for analysis of glucose, lactate, and plasma urea nitrogen (PUN). A third tube of 415 
blood was collected using 10-mL serum sampling tubes (Vacutainer, Becton Dickinson, 416 
Franklin Lakes, NJ) to obtain serum for IGF-1 analysis. Blood samples in tubes containing 417 
EDTA were immediately centrifuged at 2,494 × g for 15 min at room temperature to recover 418 
plasma. Plasma was transferred to 5-mL plastic tubes, capped, and frozen at -20ºC for 419 
subsequent analysis of PUN, glucose, and lactate. Serum samples were allowed to coagulate for 420 
1 h at 4ºC, then samples were centrifuged, and serum collected and stored as described for 421 
plasma. In addition, 0.5 mL of plasma from tubes containing EDTA were transferred into 96 422 
well vials and stored at -20ºC until shipment to Pfizer Animal Health (Florham Park, NJ) for 423 
analysis of menthol and metabolites of menthol, which include p-menthane-3,8-diol (II), p-424 
menthane-3,9-diol (III), 3,8-oxy-p-menthane-7-carboxylic acid (IV), and 3,8-dihyroxy-p-425 
menthane-7-carboxylic acid (V). 426 
Feed intakes were monitored daily, and unconsumed feed was removed from the bunk, 427 
weighed, and dried at weekly intervals or as needed to determine actual DMI.  428 
 Chemical Analyses 429 
 Glucose and lactate concentrations in plasma were analyzed using the YSI 2300 STAT 430 
Plus Glucose and L-lactate Analyzer (YSI Inc., Yellow Springs, OH). Concentrations of PUN 431 
were determined according to procedure described by Marsh et al. (1965) using the Auto 432 
  
82 
 
Analyzer II (Seal Analytical, Mequon, WI). Insulin-like glucose factor 1 was prepared using the 433 
IGF-1 enzyme-linked immunosorbent assay kit (Immunodiagnostic Systems Inc., Fountain 434 
Hills, AZ), and was measured using the Wallac Victor 2 1420 Multilabel Counter (PerkinElmer, 435 
Waltham, MA).  436 
Measurements of menthol and metabolites of menthol in plasma were determined as 437 
follows: the reference standard solution was prepared by weighing 2 mg of menthol and 438 
transferring it into a vial. One milliliter of acetonitrile was added and mixed. Serial dilutions 439 
were made to obtain concentrations of 2,000; 1,000; 200; 100; and 20 µg/mL in acetonitrile. 440 
Aliquots of the solutions were injected to obtain a standard curve for quantification. Lab 441 
standard solutions were prepared by transferring 250 µL of 20 µg/mL menthol in acetonitrile 442 
solution into a 5-mL volumetric flask containing approximately 4 mL plasma; then diluted to 443 
volume with plasma and mixed. This provided a theoretical concentration of 1,000 µg/mL 444 
menthol in plasma. Further dilutions of the 1,000 µg/mL stock solution were made to obtain 20 445 
µg/mL and 200 µg/mL solutions of menthol in plasma for subsequent runs. The 200 µg/mL 446 
solution was prepared by transferring 100 µL of the 1,000 µg/mL stock solution into a vial 447 
containing 400 µL of bovine plasma and mixed. The 20 µg/mL solution was prepared by 448 
transferring 100 µL of the 200 µg/mL stock solution into a vial containing 900 µL of bovine 449 
plasma and mixed. The lab standard solutions were stored in the refrigerator at 4ºC until 450 
analysis. Sample preparation occurred as follows: 50 µL of plasma was transferred into a well 451 
containing 200 µL of acetonitrile and mixed 1 min. The sample was centrifuged at 1,700 × g for 452 
5 min at room temperature. The supernatant was transferred into a microvial (e.g. 300 µL 453 
capacity) for analysis. 454 
 Metabolites of menthol were analyzed by gas chromatography/mass spectrophotometry. 455 
Two microliters of sample were injected into the Agilent 7890A GC (Agilent Technologies, 456 
Inc., Santa Clara, CA) with an injection port temperature of 100ºC and equipped with a 30 m × 457 
0.250 mm × 0.25 µm film, HP-5 MS column (Agilent Technologies, Inc., Santa Clara, CA). 458 
Initial oven temperature was 50ºC, held for 1 min, and then increased at a rate of 40ºC/min to a 459 
final oven temperature of 250ºC. Helium was used as the carrier gas held constant at 13.8 psi. 460 
The Agilent mass spectrometer 5975C, EI source (Agilent Technologies, Inc., Santa Clara, CA) 461 
was used as the detector, and had source and quad temperatures of 230ºC of 150ºC, 462 
respectively.  463 
  
83 
 
 In Vitro 464 
Ruminal fluid was collected from a ruminally fistulated Holstein steer at 0600 h 465 
(approximately 2 h prior to feeding). The diet of the donor steer consisted of 7% ground brome 466 
hay, 8% corn steep liquor, 80.2% steam-flaked corn, 2.16% feed additive premix, and 2.64% 467 
vitamin/mineral premix. Ruminal fluid was placed directly into pre-warmed insulated water 468 
jugs to maintain temperature, and transported 2 km to the Pre Harvest Food Safety Laboratory 469 
located on the Kansas State University campus. Ruminal fluid was strained with 4 layers of 470 
cheese cloth, placed into separatory funnels, and incubated at 38ºC for approximately 1 h to 471 
allow ruminal fluid to stratify. The bottom sediment was removed, and the bacteria-rich middle 472 
layer of strained ruminal fluid was mixed with McDougal’s buffer (150 mL of McDougal's 473 
buffer was combined with 50 mL ruminal fluid/flask), and added to each Ankom fermentation 474 
flask (Ankom Technology, Macedon, NY). Substrate used for each fermentation flask consisted 475 
of 85% corn, 5% soybean meal, and 10% alfalfa, and total substrate in each flask was 1 g. The 476 
study was conducted as a randomized complete block design with treatments consisting of 0, 477 
0.3, 0.03, or 0.003% menthol. Crystalline menthol was mixed with ethanol to obtain a 3% 478 
menthol solution, and then the 3% menthol solution was diluted with ethanol to equal 0.3, 0.03, 479 
or 0.003% menthol (substrate DM). Ethanol was used for control treatments to maintain 480 
constant volume between treatments. Menthol mixtures were added at a rate of 0.1 mL/flask, 481 
with five flasks/treatment. Three bottles containing no substrate served as blanks. Once all the 482 
components were added to fermentation flasks, bottles were capped with the Ankom pressure 483 
module (Ankom Gas Production System, Ankom Technology, Macedon, NY) and placed into a 484 
Precision reciprocal shaking bath  (Thermo Electron Corporation, Maretta, OH) maintained at 485 
39ºC for 24 h. Gas pressure was measured every 5 min. Once 24 h was complete, flasks were 486 
removed from the shaker and final pH was determined using a Thermo Orion benchtop pH 487 
meter (model 230 A, Thermo Fisher Scientific Inc., Waltham, MA). Finally, 4 mL of the flask 488 
fluid layer were mixed with 1 mL metaphosphoric acid and frozen overnight (-20ºC). After 489 
thawing, 2 mL of each mixture were placed into micro centrifuge tubes and centrifuged at 490 
17,000 × g for 10 min. Supernatant was removed, placed into gas chromatography vials, and 491 
stored in a freezer at -20ºC until VFA analysis. Remaining samples in fermentation flasks were 492 
placed into 19.0 × 12.7 cm aluminum pans and dried for 24 h at 105ºC to determine IVDMD.  493 
  
84 
 
Calculations of IVDMD were as follows: substrate weight – (dry pan weight – initial pan 494 
weight – average residue weight of blanks) 495 
 Volatile Fatty Acid Analysis 496 
One milliliter of supernatant was pipetted into 12 × 75 tubes, 50 µm of 6N sodium 497 
hydroxide were added, and tubes were then vortexed. Pivalic internal standard was added at a 498 
rate of 3 mL/tube and mixed (final pivalic acid internal standard concentration was 3 mM). One 499 
milliliter of the mix was transferred to a gas chromatography vial and refrigerated at 4ºC until 500 
analysis. Standard was prepared by weighing 19.2 mg Li-Lactate into a 25-mL volumetric flask. 501 
The flask was filled with pivalic acid internal standard (0.2 g pivalic acid, 2.52 g oxalic acid, 502 
and 6.13 g formic acid mixed in 500 mL volumetric flask filled to volume with dionized water 503 
and mixed). The analysis was carried out using a HP 5890 GC (Agilent Technologies, Santa 504 
Clara, CA) equipped with a flame ionization detector and a 2 m × 2 mm Carbopak B-DA 505 
column (Supelco, Inc., Bellefonte, PA) using nitrogen gas as the carrier gas. The injection and 506 
detector temperature was 200ºC, oven temperature was 175ºC and with a flow rate of 24 mL per 507 
min.  508 
 Statistical Analyses 509 
Feedlot performance was analyzed using the MIXED procedure of SAS version 9.2 510 
(SAS Inst. Inc., Cary, NC), using menthol as the fixed effect, and weight block as the random 511 
effect. Animal was the experimental unit. Blood measurements and BW were analyzed as 512 
repeated measures using the MIXED procedure of SAS. The repeated measures statement 513 
included time nested within d and the subject as animal nested within treatment. Menthol, time 514 
within d, and menthol × time within d were included in the model statement as fixed effects. 515 
The random effect was weight block, and animal was the experimental unit. The model 516 
statement for feed fed daily (DM basis) included menthol, d, and menthol × d as fixed effects 517 
with d as the repeated measure, and weight block as the random effect. Menthol and metabolites 518 
of menthol were analyzed as repeated measures using the MIXED procedure of SAS. Menthol, 519 
h, and menthol × h were the fixed effects, and block was the random effect. The repeated 520 
measures statement included h. Gas production for in vitro fermentations was analyzed using 521 
repeated measures with the MIXED procedure of SAS. The model statement included menthol, 522 
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time and menthol × time. The random effect was replication and the repeated statement 523 
included time. VFA, pH, and IVDMD were analyzed using the MIXED procedure of SAS. The 524 
model statement included menthol as the fixed effect and replicate as the random effect. The 525 
LSMEANS statement was used for means and standard error calculations, and the PDIFF option 526 
used for separation of means. Separations of means were determined to be significant at α level 527 
≤ 0.05. 528 
. 529 
 Results and Discussion 530 
Two animals were removed from the study. One was removed from the 0.003% menthol 531 
group due to a displaced abomasum, and the other was removed from the 0% menthol group 532 
due to a physical injury that required treatment using steroidal anti-inflammatory medications.  533 
 Growth Performance 534 
Limited information is available on the effects of menthol supplementation in growing 535 
animals, and no studies have been published with respect to its effects on finishing cattle. We 536 
observed a menthol × time within d interaction (P < 0.01) for BW. The treatment containing 537 
0.3% menthol had the lowest BW d 1 to 22 during menthol administration; however, BW 538 
measurements on d 22 and 30 were comparable to the other treatments (figure 4.1). 539 
Additionally, BW increased 6 h after feeding for all treatments, indicating a greater amount of 540 
gut fill from steers eating the majority of their feed after delivery. Soltan (2009) observed a 541 
decrease in live BW (P < 0.05) in dairy calves the first month post weaning when an essential 542 
oil mixture containing menthol was administered at 15.6, 31.2, or 46.8 mg/L in drinking water 543 
compared to calves that did not receive the essential oil mixture. The authors also observed an 544 
increase in BW the second and third month post-weaning (P < 0.05) for calves receiving 15.6 545 
mg/1L drinking water when compared to control calves, but BW of calves receiving 31.2 and 546 
46.8 mg/L of essential oil were not different (P > 0.05) than control calves. Toghyani et al. 547 
(2010) reported an increase in BW of chicks at 28 d of age (P < 0.05) but no difference at 42 d 548 
of age (P > 0.05), when dried peppermint was added to broilers diets at 4 or 8 g/kg. Similarly, 549 
Al-Kassie (2010) supplemented chicks with 0.25%, 0.5%, 1.0%, or 1.5% dried peppermint and 550 
observed an increase in BW (P < 0.05) for all peppermint supplemented broilers when 551 
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compared to control broilers. Soltan et al. (2010) administered an essential oil mixture 552 
containing menthol to dairy cows at rates of 0, 16, 32, and 48 mg/L mixed into drinking water. 553 
The authors observed an increase in BW (P < 0.05) for the cows receiving 16 and 32 mg/L 554 
essential oil when compared to either the control or cows receiving 48 mg/L essential oil. 555 
Differences in BW in the current study may be partly attributed to the fact that steers fed 0.3% 556 
menthol consumed less feed initially as indicated in figure 4.2. Feed deliveries to cattle fed 557 
0.3% menthol had the greatest decrease (P < 0.05) compared to the three other treatments until 558 
d 13. 559 
Average DMI over the entire 30 d feeding period were not different (P = 0.25) among 560 
treatments (table 4.2); however, a menthol × d interaction was observed (P < 0.01) for amount 561 
of feed fed daily. Steers fed 0.3% menthol consumed the least d 2 to d 13, at which point feed 562 
delivered to cattle fed 0.3% menthol was similar to that of the other three treatments (figure 563 
4.2).  The decreased daily feed deliveries in cattle fed 0.3% menthol was attributed to the 564 
stronger taste and aroma of menthol delivered at 0.3% of the diet DM compared to that of the 565 
other treatments, evident by the dramatic decrease in feed delivered at the initiation of the trial. 566 
Steers fed 0.3% menthol appeared to adapt to the increased aroma and taste of menthol and 567 
began to consume amounts equivalent to 0, 0.003, and 0.03% menthol treatments d 13 of the 568 
experiment. Soltan et al. (2010) observed a decrease in DMI (P < 0.05) when an essential oil 569 
mixture was added to drinking water of dairy cattle when compared to control cattle. Soltan 570 
(2009) also reported a decrease (P < 0.05) in intake for weaned dairy calves receiving an 571 
essential oil mixture the first 2 wk post-weaning, which concurs with our findings for animals 572 
fed 0.3% menthol. Studies performed using broiler chicks reported either no differences in feed 573 
intake with addition of dried peppermint to the diet (Ocak et al., 2008; Toghyani et al., 2010), or 574 
a decrease with addition of a 8 g/kg of dried peppermint to diets of broilers (Al-Kassie, 2010). 575 
Feed intakes in the current trial may have been affected by frequent handling of the animals as 576 
steers never consuming amounts equal to pre-trial DMI.  577 
Average daily gain and feed efficiency were unaffected (P > 0.05; table 4.2) by addition 578 
of menthol to diets of steers, which is in agreement with results reported by Ocak et al. (2008) 579 
and Taghyani et al. (2010) for broilers. Additionally, Soltan (2009) observed no effect on ADG 580 
or feed efficiency (P > 0.05) in dairy calves when a menthol mixture was added to drinking 581 
water. Contradicting our results, Maenner et al. (2011) fed 300 mg/kg DM of essential oil 582 
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mixture containing anise, clove, and peppermint oils or anise, clove, and cinnamon oils to 583 
piglets post-weaning. Live performance and ileal digestibly were recorded. The authors 584 
observed no improvement in ADG, but G:F was greater (P < 0.01) for piglets supplemented 585 
with peppermint oil mixture, and they attributed improvements in G:F to increased ileal 586 
digestibility of CP and AA. Overall, the lack of differences in animal performance in the current 587 
study may potentially be explained by the ability of menthol to affect growth in younger 588 
animals by increasing digestion, but as animals age the effect is no longer observed (Toghyani 589 
et al., 2010). Steers in our trial were approximately one year of age and may have responded 590 
differently than younger animals. Additionally, we did not examine digestibility of feed with 591 
menthol supplementation and therefore can’t conclude whether or not menthol affects digestion 592 
for cattle fed a finishing diet. Our results in the in vitro portion of the experiment showed no 593 
differences in VFA profiles of ruminal microorganisms from ruminal fluid of a donor steer fed 594 
93% concentrate, suggesting rumen fermentation was not affected by menthol supplementation.  595 
 Blood Parameters 596 
 We observed a menthol × time within d interaction (P < 0.01; figure 4.3) with addition 597 
of menthol to the diets of steers. Insulin-like growth factor 1 plays an important role in growth 598 
of developing animals due to its impact on cell growth, proliferation, and metabolism (Micke et 599 
al., 2010). Animals fed 0.003% menthol started out with a higher IGF-1 concentration 600 
compared to the other three treatments. At d 9 and 16, steers fed 0.003% menthol had 601 
comparable IGF-1 concentrations to steers fed 0% menthol until d 23. After d 23, 602 
concentrations in steers fed 0 or 0.003% menthol began to decrease to similar concentrations as 603 
the other two treatments (figure 4.3). Treatments containing 0.03 or 0.3% menthol started out 604 
the same as steers fed 0% menthol, but on d 9 and 16 the concentrations were lower than steers 605 
fed 0 or 0.003% menthol. To the authors knowledge IGF-1 concentrations with menthol 606 
supplementation have not been previously reported in other published experiments making it 607 
difficult to extrapolate and compare information. We concluded steers fed 0.003% menthol had 608 
no effect on IGF-1 concentration due to IGF-1 concentrations being similar to steers fed 0% 609 
menthol, but steers fed 0.03, or 0.3% menthol had a negative effect in IGF-1 concentrations 610 
until d 23.  611 
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Plasma urea nitrogen (PUN) concentration can be used as an indicator of muscle growth 612 
or protein degradation, and was observed to not be affected by menthol supplementation to 613 
steers. No menthol × time within d interaction or effect of menthol (P > 0.05; figure 4.4) were 614 
observed for plasma PUN concentrations, but an effect of time within d (P < 0.01) was observed 615 
with PUN measurements being different at each time point within d. To the authors knowledge 616 
there is no data published reporting effects of menthol on PUN concentrations. The lack of 617 
differences observed in PUN concentrations suggests protein degradation is not being affected 618 
with addition of menthol to diets of cattle.  619 
We observed no menthol × time within d interaction for plasma glucose or lactate 620 
concentrations (P > 0.05; figures 4.5 and 4.6, respectively) between treatments. Time of d had 621 
an effect (P < 0.01) on glucose and lactate concentrations with concentrations varying at each 622 
sampling time. Glucose and lactate concentrations are associated with carbohydrate and lipid 623 
metabolism, and are important components of cellular metabolism. There is limited data 624 
available to compare blood metabolite measurements that include glucose and lactate, 625 
concentrations; however, Soltan (2009) measured serum glucose of calves administered an 626 
essential oil mixture through their milk replacer. The author observed no difference (P > 0.05) 627 
in glucose concentration for calves receiving 94 or 187 mg/d of essential oils compared to the 628 
control, but for the calves receiving 281 mg/d serum glucose concentration was increased (P < 629 
0.05) by 26.4% when compared to control calves. The differences observed between our study 630 
and that of Soltan (2009) may be due to age differences of animals or route of administration. 631 
Menthol administered as a liquid may be absorbed more quickly than if it were fed in a ration 632 
potentially explaining why calves in the Soltan study receiving 281 mg/d had increased glucose 633 
values, whereas steers in our study fed 0.3% menthol did not.  634 
We concluded menthol does not have an effect on PUN, glucose, or lactate 635 
concentrations; however, increased concentrations of menthol may reduce the amount of 636 
circulating IGF-1 concentration. 637 
Menthol is a lipid-soluble substance that is transported to the liver after ingestion, or can 638 
be absorbed through skin or respiratory epithelium. Menthol is hydroxylated in the liver, 639 
conjugated with glucuronide, and then circulated to the kidneys for excretion in urine (Eccles, 640 
1994). Metabolites of menthol are the products of menthol after it is hydroxylated and 641 
conjugated. Some metabolites of menthol found in urine of rats after ingestion include: p-642 
  
89 
 
menthane-3,8-diol (II), p-menthane-3,9-diol (III), 3,8-oxy-p-menthane-7-carboxylic acid (IV), 643 
and 3,8-dihyroxy-p-menthane-7-carboxylic acid (V; Madyastha and Srivatsan, 1988), and may 644 
potentially be present in cattle. Metabolites of menthol in plasma were measured, and we 645 
observed no menthol × h interaction (P = 0.71; figure 4.7), but an effect of menthol (P = 0.05) 646 
and an effect of time (P < 0.01) were observed with concentrations of menthol being different at 647 
different time points. At some of the sampling time points at least one steer fed 0% menthol 648 
contained menthol metabolites in plasma. The reason for this is unknown, but it is conceivable 649 
that some menthol was inhaled by control steers due to the volatility of menthol, and steers 650 
being housed in close proximity to each other. Menthol has been utilized as a stimulant of cold 651 
receptors in the upper airway of human patients in respiratory discomfort (Nishino et al., 1997). 652 
It may be possible for metabolites of menthol to appear in the blood stream through passive 653 
diffusion once inhaled into the lungs. Additionally, at h 702 the high menthol treatment 654 
demonstrated a large increase in metabolites when compared to the other treatments due to one 655 
animal having a high concentration of metabolites in the blood. Wu et al. (2010) observed the 656 
half life of hard capsules containing peppermint oil to be 1.91 h and for a soft capsule 657 
containing peppermint oil to be 1.4 h in beagle dogs. The half life of menthol metabolites in 658 
bovine plasma is not known and it may be metabolized and excreted rather quickly which 659 
would explain why some sampling times cattle receiving menthol had no metabolites of 660 
menthol in plasma. 661 
 In Vitro 662 
Menthol is an essential oil that has been observed to have antibacterial activity and may 663 
affect fermentation products of ruminal microorganisms (Eccles, 1994). Menthol had no effect 664 
on in vitro concentrations of acetate, propionate, butyrate, isobutyrate, 2- and 3-methyl 665 
isovalerate, valerate, or lactate (P > 0.10; figures 4.8 and 4.9) indicating menthol had no effect 666 
on rumen fermentation. Hosoda et al. (2005) conducted an in vivo experiment in which rumen 667 
fermentation of dairy cattle were evaluated after addition of an essential oil mixture containing 668 
menthol. Cows were assigned randomly to either a control diet or a diet containing 5% of 669 
peppermint (DM basis) for 8 d. In agreement with our observations, the authors reported no 670 
difference for total VFA concentration, and molar rate of acetate, propionate, and butyrate (P > 671 
0.05) between treatments. In contrast to our results, Agarwal et al. (2009) reported a linear 672 
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increase in the molar proportion of acetate (P < 0.05) and a linear decrease in the molar 673 
proportion of propionate (P < 0.001) when cultures of mixed ruminal microbes were 674 
supplemented with 0, 0.33, 1 or 2 mM peppermint oil. A quadratic effect for molar proportion 675 
of butyrate (P < 0.01) was observed with cultures containing 1 mM peppermint oil having the 676 
highest butyrate concentration and containing 0 or 2 mM having the lowest concentration. The 677 
authors speculated that differences in VFA concentrations were due to accumulation of 678 
molecular hydrogen as a result of decreased methanogenesis. Ando et al. (2003) observed a 679 
decrease (P < 0.01) in propionate concentration in ruminal fluid from cannulated Holstein steers 680 
that received 200 g dried peppermint daily compared to no menthol supplementation. The 681 
authors postulated that antimicrobial effects of menthol may have had an adverse effect on 682 
ruminal fermentation, thereby decreasing VFA production. Lack of congruence among studies 683 
may be due to differences in the initial diet of the donor animal, potentially resulting in different 684 
microfloral populations in ruminal fluid. 685 
 Some bacterial, protozoal, or fungal species may be more susceptible to menthol then 686 
others. Zmora et al. (2012) conducted an in vitro batch fermentation trial with 5 doses of dried 687 
peppermint leaves (0, 2.3, 8.17, 16.34, and 23.35 mg). The authors observed a quadratic effect 688 
(P < 0.005) with 16.34 and 23.35 mg peppermint decreasing the methanogen population. 689 
Additionally, linear and quadratic effects (P < 0.05) were observed in bacterial and protozoal 690 
populations with 8.17 mg peppermint having the greatest decrease in bacteria, and 16.34 mg 691 
inducing the greatest decrease in protozoa. These results confirm the antimicrobial properties of 692 
menthol; however, the diet of the donor steer in our trial was receiving 93% concentrate. The 693 
high concentrate diet may have changed the microbial population to favor microbes that were 694 
less susceptible to menthol. This also may possibly explain the lack of an effect on VFA 695 
concentrations in our study. 696 
Terminal pH and IVDMD were not different between treatments (P > 0.10; figures 4.10 697 
and 4.11, respectively). In agreement, Zmora et al. (2012) observed no differences between 698 
treatments for pH and IVDMD (P > 0.05) when mentha piperita L. was added at rates of 2.33, 699 
8.17, 16.34, or 23.35 mg to batch fermentation incubation vessels. Contradicting our results, 700 
Agarwal et al. (2009) observed a quadratic decrease (P < 0.05) in in vitro true digestibility 701 
(IVTD) of feed with addition of 0.33, 1.0, or 2.0 µL/mL peppermint oil to buffalo rumen liquor 702 
with 1.0 µL/mL peppermint having the greatest decrease in IVTD. Additionally, Ando et al. 703 
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(2003) observed a decrease in rumen pH with addition of 200 mg dried peppermint to the diet of 704 
cannulated steers. Differences observed between studies may reflect the differences in source of 705 
menthol, time of sampling, or diet of donor animals. 706 
Menthol has been administered to cattle in the form of peppermint and has consistently 707 
demonstrated decreases in methane production (Argwal et al., 2009; Zmora et al., 2012). We 708 
observed no menthol × time interaction (P > 0.10) for fermentative gas production; however, an 709 
effect of menthol (P < 0.01) was observed. Addition of menthol decreased the amount of 710 
fermentative gas produced at all menthol inclusion rates (figure 4.12). Agarwal et al. (2009) 711 
observed an increase (P < 0.01) in total gas production with addition of 0.33 and 1.0 µL/mL 712 
peppermint oil in vitro whereas 2.0 µL/mL peppermint resulted in no difference (P > 0.05) in 713 
total gas produced by ruminal microflora. The concentrations of menthol used in the trial by 714 
Agarwal et al. (2009) were higher than that used in our experiment, which may explain 715 
differences between experiments. Jani et al. (2010) performed a study in which gas production 716 
was measured in vitro using rumen fluid from 2 cannulated sheep. Peppermint oil was added at 717 
14 or 40 µL/g DM to ruminal inoculum and gas measurements were recorded. The authors 718 
observed a decrease in volume of gas produced (P < 0.05), which is in agreement with our 719 
results. The decrease in total gas production in the current trial may be caused by antimicrobial 720 
activity of some microbial species, as evidenced by the decrease in methanogenesis noted by 721 
Argwal et al. 2009.  722 
In conclusion, addition of menthol to diets of cattle had little or no effect on growth 723 
parameters measured in this trial; however, in vitro fermentative gases were reduced suggesting 724 
menthol may alter ruminal bacterial populations without having a negative effect on VFA 725 
production. 726 
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 794 
Table 4.1: Diet Composition, DM basis 795 
 Menthol, % diet DM 
Ingredients, % DM basis 0% 0.003% 0.03% 0.3%  
Steam flaked corn 50.39 50.39 50.34 49.89 
Wet corn gluten feed 33.640 33.637 33.660 33.840 
Corn silage 12.00 12.00 12.00 12.00 
Feed additive premix
1 
2.16 2.16 2.16 2.16 
Vitamin/mineral premix
2 
0.07 0.07 0.07 0.07 
    Limestone 1.44 1.44 1.44 1.44 
    Salt 0.30 0.30 0.30 0.30 
Menthol
3 
- 0.003 0.03 0.3 
Calculated composition,% 
   CP 14.00 14.00 14.00 14.00 
   Ca 0.62 0.62 0.62 0.62 
   P 0.51 0.51 0.51 0.51 
   K 0.70 0.70 0.70 0.70 
   NDF 20.08 20.08 20.08 20.10 
1
Formulated to provide 300 mg/d monensin and 90 mg/d tylosin (Elanco Animal Health, 796 
Greenfield, IN) in a ground corn carrier. 797 
2
Formulated to provide 2,200 IU/kg vitamin A; 22 IU/kg vitamin E; 10 mg/kg added Cu; 60 798 
mg/kg added Zn; 60 mg/kg added Mn; 0.5 mg/kg added I; 0.25 mg/kg added Se; and 0.15 799 
mg/kg added Co.  800 
3
Menthol provided by Ind-Swift Laboratories Limited (Dover, DE).801 
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 802 
Table 4.2: Effect of menthol on feedlot performance
 
803 
 Menthol, % of diet DM   
Item 0%  0.003%  0.03% 0.3%     SEM P-value 
ADG, kg 0.55 0.54 0.51 0.48 0.17 0.98 
DMI, kg 7.51 7.50 7.80 7.02 0.36 0.25 
G:F 0.067 0.056 0.059 0.065 0.02 0.97 
 804 
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Figure 4.1: Effect of menthol on BW obtained from Holstein steers on days 1, 9, 16, 23, and 30, and at hour 0 on d 1 then h 0, 805 
6, 12, 18, and 24 on d 9, 16, 23, and 30.  806 
Treatments consisted of 0, 0.003, 0.03, and 0.3% diet DM menthol.  807 
Effect of menthol × time within d interaction P < 0.01; d 9, 16, 23 at h 0, 18 and 24, steers receiving 0.3% menthol had lower BW 808 
than other treatments; effect of menthol P = 0.15; effect of time within d P < 0.01;  SEM = 10.53. 809 
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 Figure 4.2: Daily feed delivered to Holstein steers (DM basis).  812 
Diets were formulated to contain 0, 0.003, 0.03, and 0.3% diet DM menthol. Arrow indicates beginning of treatment administration. 813 
Menthol × d interaction, P < 0.01, steers receiving 0.3% menthol had lower feed deliveries d 2 thru 13; effect of menthol, P = 0.31; 814 
effect of d, P < 0.01.  SEM = 0.78. 815 
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 818 
Figure 4.3: Effects of menthol on IGF-1 concentration from Holstein steers on days 1, 2, 9, 16, 23, and 30, and at hours 0, 6, 12, 819 
18, and 24.  820 
Treatments consisted of 0, 0.003, 0.03, and 0.3% diet DM menthol. Arrow indicates beginning of treatment administration. 821 
Menthol × time within d interaction P < 0.01; steers receiving 0.003% menthol had higher IGF-1 concentrations d 1 and 2; d 9 and 16, 822 
0% and 0.003% menthol had higher IGF-1 concentrations compared to 0.03 and 0.3% menthol; effect of menthol P = 0.26; effect of 823 
time within d P < 0.01; SEM = 16.2.  824 
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Figure 4.4: Effects of menthol on plasma urea nitrogen concentration from Holstein steers on days 1, 2, 9, 16, 23, and 30, and 826 
at hours 0, 6, 12, 18, and 24. 827 
Treatments consisted of 0, 0.003, 0.03, and 0.3% diet DM menthol. Arrow indicates beginning of treatment administration.  828 
Menthol × time within d interaction P = 0.11; effect of menthol P = 0.65; effect of time within d P < 0.01; SEM = 0.30. 829 
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Figure 4.5: Effects of menthol on plasma glucose concentration. 832 
Blood samples were obtained from 50 Holstein steers on days 1, 2, 9, 16, 23, and 30, and at hours 0, 6, 12, 18, and 24. Treatments 833 
consisted of 0, 0.003, 0.03, and 0.3% diet DM menthol. Arrow indicates beginning of treatment administration. 834 
Menthol × time within d interaction P = 0.12; effect of menthol P = 0.46; effect of time within d P < 0.01; SEM = 0.17. 835 
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Figure 4.6: Effects of menthol on plasma lactate concentration for Holstein steers on days 1, 2, 9, 16, 23, and 30, and at hours 837 
0, 6, 12, 18, and 24.  838 
Treatments consisted of 0, 0.003, 0.03, and 0.3% diet DM menthol. Arrow indicates beginning of treatment administration. 839 
Menthol × time within d interaction P = 0.87; effect of menthol P = 0.50; effect of time within d P < 0.01;   SEM = 0.28. 840 
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 842 
Figure 4.7: Concentration of menthol metabolites in plasma obtained from Holstein steers.  843 
Diets were formulated to contain 0 (◊), 0.003 (■), 0.03 (▲), and 0.3% (○) diet DM menthol (Ind-844 
Swift Laboratories Limited, Dover, DE). Diets were delivered to pens once daily according to 845 
the following feed schedule: barn A was fed at approximately 1500 h, barn B was fed at 846 
approximately 1600 h, and barn C was fed at approximately 1700 h daily, arrow indicates 847 
feeding relative to time of blood collection. Day 1; h 12, 18, 24, and d 2; h 6 (plate 1), d 9; h 0, 6, 848 
12, and 18 (plate 2), d 16; h 6, 12, 18, 24 (plate 3), d 23; h 0, 6, 12, 18 (plate 4), d 30; h 0, 6 849 
(plate 5) 850 
Menthol × h interaction, P = 0.71; effect of menthol, P = 0.05; effect of h, P < 0.01.           SEM 851 
= 17.29.  852 
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Figure 4.8: In vitro production of major VFA by ruminal microflora with addition of 0, 0.003, 0.03, 0.3% (DM) menthol.  859 
Effect of menthol, P > 0.10. 860 
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Figure 4.9: In vitro fatty acid production by ruminal microflora with addition of 0, 0.003, 0.03, 0.3% (DM) menthol.  863 
Effect of menthol, P > 0.10. 864 
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Figure 4.10: Effect of 0, 0.003, 0.03, 0.3% menthol (substrate DM) on 24 h in vitro 
fermentation terminal pH. 
Effect of menthol, P = 0.21; SEM = 0.025 
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Figure 4.11: Effect of 0, 0.003, 0.03, 0.3% menthol (substrate DM) on IVDMD. 
Effect of menthol, P = 0.77; SEM = 0.023. 
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Figure 4.12: Effect of 0, 0.003, 0.03, 0.3% menthol of substrate DM on in vitro fermentative 
gas production. 
Menthol × time interaction, P > 0.05; effect of menthol, P < 0.001; effect of time, P < 0.01; 
SEM = 29.32 
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